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Influenza C is a virus found throughout the world that can cause respiratory illness, ranging 
from mild colds to pneumonias. Typically affecting younger children, it is a virus which can 
cause considerable illness and complications, and yet research into the virus is lacking. 
This study aimed to identify the prevalence of influenza C in Lancaster, and to determine the 
current seropositivity levels in the study population. 
148 participants were recruited to the study – 77 asymptomatic and 71 symptomatic. 
Participants were asked to provide a nasal or nasopharyngeal swab and/or a serum sample.  
The swabs were analysed via polymerase chain reaction (PCR) and the serum samples by 
enzyme-linked immunosorbent assays (ELISA) and, of the samples tested via ELISA, 106 
were positive (82%) and 23 were negative. Two swab samples also appeared positive for 
influenza C following PCR and so were sent for deep sequencing. A further seven mixed 
cDNA samples were also sent for deep sequencing to allow for comparison between different 
population groups etc. 
Overall, it was found that influenza C is prevalent in the Lancaster area, with the entire study 
population having some level of exposure to the virus previously, although only 82% of 
participants met the threshold to be classed as seropositive, and two participants were actively 
carrying the live influenza C virus.  
Further work needs to be done to analyse the seasonality of the virus and discover whether 
the virus has the same impact in the UK as it does in other parts of the world. As positive 
samples have been found and most of the population have influenza C antibodies, it provides 





I.I Influenza C 
Influenza C (fluC), first isolated in 1947 (1), is a virus that causes respiratory illness and 
infections. Despite being known about for over 60 years, fluC has been overlooked and 
research into this virus is currently lacking.  
I.II Orthomyxoviridae 
Influenza C is from the genus Influenzavirus C and family Orthomyxoviridae (2, 3), which 
also contains the other genera Influenzavirus A (fluA), Influenzavirus B (fluB), Thogotovirus, 
and Isavirus (3). Each virus has a genome composed of single-stranded RNA, varying from 
six (Thogotovirus) to eight (fluA, fluB, and Isavirus) segments (3). The influenza viruses are 
all commonly found in humans and some are also present in other species. Thogotovirus can 
also infect humans and livestock but is transmitted via ticks, whereas the fifth genus, 
Isavirus, is solely found in salmon and is known as infectious salmon anaemia virus (3). 
There has also recently been suggestion of an Influenzavirus D, but there is little research into 
this area (4). 
I.III Influenza C Genome 
FluC is an enveloped virus, and its genome comprises  seven segments of single stranded 
RNA that is negatively polarised - PB2, PB1, P3, HE (or HEF), NP, MP, NS – numbered 1-7 
respectively (5-7), and the ends of the RNA segments, 5’ and 3’, are complimentary (5). The 
segments code for nine proteins; three polymerase proteins (PB2, PB1, and P3), a 
haemagglutinin-esterase surface glycoprotein (HE) (see Figure 1), a nucleoprotein (NP), a 





Figure 1 - X-ray structure of HE glycoprotein (Rosenthal et al. 1998, presented by PDB 
2015) (9, 10)  
The structure of the HE glycoprotein is comprised of many different protein chains, and each 
individual protein chain is coloured by position. 
The role of each protein varies; PB2, PB1 and P3 are all part of the fluC RNA polymerase 
(6). HE takes part in receptor binding/destroying (acetylesterase) and membrane 
forming/fusion activities and forms a spike on the virion (7, 10-14). NP, when it encapsidates 
the RNA polymerase and RNA forms a viral ribonucleoprotein complex (vRNP) (15). M1 
lies beneath the lipid bilayer and provides rigidity to the envelope, with CM2 also found in 
the membrane and provides a channel for chloride ions (16-18). NS1 aids viral mRNA 





Figure 2 – Structure of fluC (Muraki and Hongo 2010) (7) 
FluC is an enveloped virus, with a central viral ribonucleoprotein complex (vRNP) 
surrounded by a lipid bilayer. Eight of the nine fluC proteins are shown - three polymerase 
proteins (PB2, PB1, and P3), a haemagglutinin-esterase fusion protein (HEF), a nucleoprotein 
(NP), a matrix (M1) and a CM2 protein, and a non-structural proteins (NS2). The NP forms 
the vRNP by encapsidating the RNA polymerase (including PB2, PB1 and P3) and RNA, and 
the HEF forms a spike on the virion, M1 lies beneath the lipid bilayer and provides rigidity to 
the envelope, whilst CM2 provides a channel in the membrane for chloride ions and NS2 acts 
as a nuclear export factor.  
I.IV Comparison of the influenza viruses  
I.IV.I Genomes 
Of the three influenza viruses, fluA and fluB are more closely related, with fluC the outlier. 
FluA and fluB both have eight RNA segments as, instead of the HE segment present on fluC, 
fluA and fluB have two separate segments – haemagglutinin (HA) and neuraminidase (NA) 
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(3, 6). Another difference between these segments is that the cytoplasmic section of the HE 
segment on fluC contains three amino acids, whereas the HA segment contains 11 to 12 (7). 
The P3 segment of fluC correlates to the PA segment on fluA and fluB, and is so named as 
when it is at a neutral pH, it does not display any acid charge features (7). 
In terms of the host range of fluC, it appears to be more closely related to fluB than it is to 
fluA. FluB is generally only found in humans, although it has been reported in seals (21, 22),  
and fluC is  mainly found in human and swine species (3), whereas fluA, in contrast, is found 
in various hosts including humans, swine, horses, and birds (3). The large avian fluA 
reservoir is nearly always the cause of the fluA pandemics (except 2009), due to the vast 
number of strains capable of reassortment. As fluB does not have a known animal reservoir, 
like fluA, it is less capable of producing a pandemic (23), and interestingly, despite fluB 
being more ‘well known’ and better documented than fluC, some studies have found more 
patients infected with fluC than fluB (24, 25). 
I.IV.II Seasonality 
Opinions on the seasonality of fluC seem to differ, and this may be due to the different 
regions and conditions where fluC is found throughout the world. One view is that unlike 
fluA, which appears to be seasonal and causes epidemics/pandemics (26-28),  fluC  and fluB 
are present in the human population all year round (3), which appears to be the case in some 
parts of Spain (25) and France (29). It does appear that there has previously been a national 
fluC epidemic in Japan in 2004 (30), and fluC often coincides with fluA and fluB infections 
(25, 28), but otherwise fluC is believed to be present in the population continuously. The 
other opinion is that fluC is seasonal and is found in the winter to early summer months, 
particularly January to June, which is the case in Japan and the Philippines (27, 30-33), Spain 
(24), Finland (28), Canada (34), France (35) , and Nigeria (36).  
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I.V Symptoms of influenza C infection 
Common symptoms of fluC are fever, cough and rhinorrhoea (33, 37), with 33% of adults 
experiencing fever (38) and 90% of  children (37). On average, symptoms last for six days 
(range 5-11 days), with a mean incubation period of four days (range 3-6 days) (38). It is also 
worth noting that infection with fluC, like fluA and fluB,  can cause some economic damage, 
due to absence from work etc. (39) and so provides another reason for studying this topic.  
The illnesses attributed to fluC are generally mild, upper respiratory tract infections in adults 
and adolescents (38, 40, 41), however in young children fluC can also cause lower respiratory 
tract infections, including bronchitis, bronchiolitis and pneumonia, with a high risk of 
complications, particularly in children under two years of age (24, 30, 33-35, 37, 42-46).  
One case documented that fluC caused an episode of acute encephalopathy (47) and in 
younger children, fluC also appears to be a common cause of gastrointestinal symptoms (35, 
37). 
It has also been found that fluC is more prevalent in children under the age of five years (35, 
48), although elderly patients have also been found to have fluC infections (35, 49). Homma 
et al. also suggested that primary fluC infections occur in those under seven years old (50), 
and so it is important that swabs from children are included in this study.  
I.V.I Transmission and replication 
In humans, fluC is spread via respiratory secretions; when the infected host coughs or sneezes 
the virus becomes airborne and is transmitted to another individual (11, 23). The virus then 
replicates in the trachea-bronchial epithelial cells (23), which is typical for influenza in 
human hosts. The activated HA/HE segment of the virus binds to sialic acid, which is present 
on host cell glycoproteins on the plasma membrane (3, 23). The entire replication of the RNA 
takes place in the nucleus of the cell (3). In contrast, avian fluA is spread via the faecal-oral 
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route (3, 11, 23). Bird species, such as ducks have receptors for the virus in their gut (3, 23), 
and it has also been documented that humans have been infected with avian strains of fluA in 
their gut (51), but there is currently no evidence for such receptors in fluC (35). 
I.VI Immune response 
I.VI.I Immunoglobulin G (IgG) 
Immunoglobulin G (IgG) is one of the five classes of Ig expressed by B cells (52). The IgG 
antigen receptor is comprised of two heavy polypeptide chains and two light polypeptide 
chains, linked by disulphide bridges (found in the constant region). Most of the chain remains 
constant between each Ig class; however the heavy-chain constant region differs between the 
four Ig classes (52). The IgG antibody is soluble and can be found in all bodily fluids, 
including blood, tears, saliva and breast milk (52). 
Interestingly, following intranasal or subcutaneous vaccination with fluA, the highest level of 
antibody found in nasal secretions was IgA. This IgA was different to the IgA found in serum 
(the nasal IgA contains extra-antigenic determinants, which differentiates it from the IgA 
found in serum), but both the serum IgA and IgG were also found in reasonable quantities in 
nasal secretions (53). In comparison, the highest level of antibody found in serum following 
vaccination was IgG. It was also of note that children were more responsive than adults to 
intranasal vaccination, and generated higher levels of antibodies (52).  
Table 1 shows a range of normal IgG antibody levels for all ages. These values were 
calculated using nephelometry, and will be used as the normal range reference values for the 
total IgG antibody levels. The range of values for adults is 639-1349 mg/dl (53, 54), which is 
similar to values in other articles (694-1618 mg/dl total IgG (55), 584-1486 mg/dl (56)). 
Other methods have been used to calculate IgG levels, including ELISA, radial 
immunodiffusion and immunoturbidimetry; one paper calculated the IgG reference values 
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using immunoturbidimetry, and found that the mean (1058 mg/dl) and median  (1073 mg/dl) 
fell within those values listed (56). Values for IgG deficiency were also included, with 
deficiency defined as <700 mg/dl total IgG (55), or below the 95% confidence interval (584 
mg/dl) (56), however it was shown that those donors who had values that would class them as 
‘deficient’ were actually healthy, and so any conclusions drawn need to be done so carefully 
(56). 
Table 1 - Normal values - total IgG antibody concentration (Joliff et al. 1982, adapted 
Agarwal et al. 2007) (53, 54) 
This shows the mean total IgG concentration expected for people in different age groups, and 
the normal range. These values will provide the basis for the expected total IgG levels for 
participants in this study. 
Age IgG, mean (range), mg/dl
Cord blood (term) 1,121 (636–1606) 
1 mo 503 (251–906) 
2 mo 365 (206–601) 
3 mo 334 (176–581) 
4 mo 343 (196–558) 
5 mo 403 (172–814) 
6 mo 407 (215–704) 
7–9 mo 475 (217–904) 
10–12 mo 594 (294–1,069) 
1 y 679 (345–1,213) 
2 y 685 (424–1,051) 
3 y 728 (441–1,135) 
4–5 y 780 (463–1,236) 
6–8 y 915 (633–1,280) 
9–10 y 1,007 (608–1,572) 




Table 2 – Normal values - fluA IgG antibody concentration (Crum-Cianflone et al. 
2012) (55) 
This table shows the normal mean and range fluA IgG levels. These values will be used to 
provide an estimation of the fluC IgG values expected to be found in this study.  
HIV-uninfected adults 
Factor Total group  
n = 24 
Robust antibody 
response n = 12 
Poor antibody response 
n = 12 
Baseline overall IgG levels, mg/dl 
Median Total IgG 1050 (890–1150) 1060 (966–1130) 933 (865–1180) 
Baseline influenza-specific IgG levels, median levels, mg/dl 
Total fluA IgG 24 (15-39) 21 (7-30) 24 (15-40) 
IgG1 17 (13-35) 15 (5-27) 22 (14-35) 
IgG2 1 (0-2) 1 (0-2) 1 (0-2) 
IgG3 3 (0-6) 1 (0-5) 3 (1-6) 
IgG4 0 (0-0) 0 (0-1) 0 (0-0) 
 
I.VI.II IgG in response to the influenza virus 
Figure 3 shows a cell infected with the influenza virus. The infected cell expresses antigens 
on the surface which the IgG binds to. Effector cells then bind to certain regions on the IgG 
antibodies, releasing cytotoxic granules and antiviral cytokines which ultimately results in 





Figure 3 – IgG response to influenza infected cells (Jegaskanda et al. 2014) (57) 
The human immune response to an influenza infection. Specific IgG antibodies against the 
specific influenza virus bind to infected cells. Natural killer cells then bind to the IgG 
antibodies which have the CD16 receptor. Perforin and granzyme B are then released by the 
natural killer cells, which are programmed to kill the infected cells. 
I.VII Antigenic variation  
I.VII.I Reassortment 
Reassortment occurs within human hosts when they are infected with two different strains of 
fluC via exchange of segments (31, 32, 58-63), and this also occurs in fluB infections (64). 
I.VII.II Antigenic drift 
All three influenza viruses are capable of antigenic drift, although it occurs at a faster rate in 
fluA and fluB (11, 15, 65). This is a process in which mutations can occur naturally in one or 
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two glycoproteins – HA and NA (15). These proteins are surface antigens on the virus and 
have slightly differing roles; HA binds to receptors on host cells whereas NA is an enzyme 
that removes the sialic acid that HA binds to, therefore freeing the virus particles from the 
host cell receptors, allowing virions to escape from the cell, and aiding the spread of the virus 
(10, 15, 22). The mutations occur within the antibody-binding sites in HA/NA and 
accumulate over time. As these mutations occur, the antibodies that the host produced can no 
longer inhibit the virus because the structure of the HA and NA has changed and no longer 
produces a match for the antibody and so the virus can therefore spread more easily (15). It is 
this process that is responsible for the annual epidemics and seasonality seen in human fluA 
and fluB infections (22). The process is slightly slower in fluC, due to the presence of the HE 
glycoprotein instead, but nevertheless it has been noted that the dominant antigenic group on 
fluC is replaced every several years (26), showing that the process does occur. 
By contrast, some papers have reported that antigenic drift does not occur in fluC, and instead 
antigenic replacement occurs (due to immune selection in those who have cross reactive 
antibodies) (25, 26). Interestingly, fluA is also capable of antigenic shift (15, 22), which can 
be seen as analogous to the process of antigenic replacement in fluC, in that both produce 




Figure 4 - Structure of a HA Monomer and Location of the Antibody-Binding Sites 
(Treanor 2004) (66)   
The haemagglutinin (HA) and neuraminidase (NA) glycoproteins on fluA are shown. When 
antigenic drift occurs, point mutations at the antibody-binding sites mean that the antibodies 
to HA/NA can no longer bind (15). 
I.VII.III Rate of nucleotide substitution  
Another aspect of antigenic variation is nucleotide substitutions, and the rate at which this 
occurs. Each segment has a different rate of nucleotide substitution, and this also differs 
between fluA, fluB and fluC, for example the rate of nucleotide substitution of the fluC HE 
segment is one ninth of the speed of the equivalent human HA segment on fluA (4.3x10-3 
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[H1] and 4.44x10-3 [H3] (15)) (6, 7). Table 3 shows the nucleotide substitution rates for all 
seven of the fluC segments. The rate of the substitutions is x 10-4 per site per year. The time 
of most recent common ancestor (t-MRCA) is also shown, along with the 95% highest 
posterior densities (HPD) for each segment.  Pi represents the average number of 
substitutions per site in the alignment.   
Table 3 – Nucleotide substitution rates for the fluC segments (Gatherer 2010) (58) 
This table shows the nucleotide substitution rates (x 10-4 per site per year) for the seven 
different fluC segments. Pi represents the average number of substitutions per site in the 
alignment.  The time of the most recent common ancestor and the 95% highest posterior 
densities are also shown. 
 
I.VII.IV Vaccine 
Due to the capabilities of the viruses to undergo antigenic variation, creating a vaccine is 
difficult. A new vaccine is produced every year, against fluA and fluB, and the epidemic 
activity of each new virus has to be predicted, in order to select which strains will be included 
(15). As fluC does not undergo changes as frequently as fluA and fluB, and in older articles it 
was thought to be less of a threat to humans,  it is not currently deemed important enough to 




In the studies previously carried out, fluC global seroprevalence appears to be over 50% (28, 
44, 67-69), with values ranging from 50% in Reunion Island (28) to 89% in Finland (27), 
although one article reports a seroprevalence rate of around 100% in those aged over 10 (46).  
With regards to the UK, seroprevalence values have been reported between 60-70% for those 
aged over 25 years (28, 70).  These slight variances throughout the world could be due to a 
number of reasons, for example it could be due to different population groups around the 
world, or there could be methodological differences such as different detection methods, 
different sample types, different sample preparation methods or different sources (people). 
It is currently accepted that antibodies against fluC are acquired early on in life, with levels 
peaking during early adulthood (42, 44, 49, 71, 72). It has also been noted that these 
antibodies can then drop away again over the age of 65 years, as shown by O’Callaghan et 
al., who found that the incidence in those over 65 was 18.3%, compared to 96% in young 
adults (68). However, despite developing these antibodies it appears that it is possible to be 
re-infected with fluC (37, 42, 49, 71), which supports the statement that fluC is capable of 















Figure 5 – Mean fluC sera antibody titres (Hilleman et al. 1953) (72) 
The mean antibody titres against fluC (1233) increase with age, with the levels plateauing in 
early adulthood. The levels then continue at a steady state.  
I.IX Epidemiology of fluC 
I.IX.I Nomenclature 
FluC viruses are named based upon a series of information; firstly the influenza virus type 
(C), then the host e.g. swine (although this is not included if the virus is isolated from 
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humans), then the geographical location, the allocated strain number, and finally the year of 
isolation.  
In contrast, fluA is currently classified into different types according to the HA and NA 
segments, and the subtypes (HA or NA) are added at the end (3, 22). There are 16 HA and 
nine NA types (3), all of which are found in avian species (10).  
I.IX.II Lineages 
Different genes are found to co-circulate in the population at any one time (73). Antigenic 
and genetic analysis of the HE segment of various fluC strains has shown that they can be 
split into six different lineages; Taylor/47, Kanagawa/1/76 (KA176), Yamagata/26/81 
(YA2681), Aichi/1/81 (AI181), Sao Paulo/378/82 (SP82), and Mississippi/80 (MS80) (6, 7, 
31). (Figure 6 shows these six different lineages, presented in a phylogenetic tree). The HE 
segment has also been classified using the alternative method of Bayesian statistics (58). The 
most recent common ancestor (MRCA) of the HE gene can be traced back to 1890, whereas 
for PB1 the most recent common ancestor is in 1944 (58) (Table 3).   
The most recent data on genome constellations is from Japan in the 1990s (58), and the most 
recent full genome was isolated in 2011 (74), and so any further changes in the fluC lineage 










Figure 6 - Phylogenetic tree of fluC virus HE genes (Matsuzaki  et al. 2003) (31) 
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The different strains can be categorised into one of six lineages - Taylor/47 (red), 
Kanagawa/1/76 (KA176) (green), Yamagata/26/81 (YA2681) (blue), Aichi/1/81 (AI181) 
(orange), Sao Paulo/378/82 (SP82) (yellow), and Mississippi/80 (MS80) (purple). 
I.X Studies testing serum for fluC antibodies 
A few studies have tested serum samples for antibodies against fluC. 
Haemagglutination inhibition assays/titres (HI) have been commonly studied, as most adult 
serum samples contain haemagglutination-inhibiting antibodies (25, 26, 28, 32, 44, 49, 61, 
67-69, 72). Despite this, HI is now quite an old method and newer methods, such as ELISA, 
have been shown to be simpler (75-77).  
ELISAs have also been used in studies to detect fluC antibodies (27, 28). One of the most 
recently published papers by Salez et al. performed both an HI and an ELISA on serum 
samples and found very similar results, with the ELISA having a high positive predictive 
value (91%) and specificity (86%), and modest sensitivity (66%) (28). One paper using an 
ELISA to detect fluA antibodies also created standard curves using known values of IgG, 
which allowed for quantification of IgG antibody levels in each sample (55). 
As described by Homma et al. newborns under the age of two months have maternal 
antibodies against fluC (49). As these antibodies wear off children become more susceptible 
to fluC infection and are likely to become infected before they develop their own antibodies. 
The antibody titres then increase and peak during adolescence/early adulthood (49, 72). Due 
to this trend, it is important to try and collect samples from patients of all age groups in order 
to try and monitor this trend. 
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I.X.I Capillary blood sampling 
Although capillary blood samples provide smaller volumes they are less painful and invasive 
then venous blood samples, making them more appealing to children, and can give similar 
ELISA results to venous blood samples, when looking for antibodies against rubella (75-77). 
Figure 7 shows the results of Vaheri et al. when comparing venous and capillary blood 
samples – the correlation coefficients between venous serum and finger-tip blood and venous 
serum and finger-tip plasma are (r) = 0.945 and (r) = 0.949 respectively (76). Vejtorp et al. 
also recommended using BD Microtainer® tubes to store the capillary blood samples prior to 
performing the ELISA, as they are simple to use and store and the samples do not degrade as 
they can do when collected on filter paper (75).  
 
Figure 7 – Comparison of venous and finger-tip (capillary) blood samples when 
performing an ELISA to detect rubella antibody levels (Vaheri et al. 1980) (76) 
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Venous and capillary blood samples were compared, and the correlation coefficients between 
venous serum and finger-tip blood and venous serum and finger-tip plasma are (r) = 0.945 
and (r) = 0.949 respectively. Both sets of results give very similar readings. 
I.XI Studies testing samples for fluC 
When looking for fluC during an active infection, nasal swabs (24, 28, 45, 47, 74), 
pharyngeal swabs (44), nasopharyngeal swabs (26, 32), oropharyngeal swabs (24), throat 
swabs (32, 47, 61, 74), nasal aspirates (44), nasopharyngeal aspirates (23, 78) and sputum 
samples (27) have been used. The general method used for analysing these was PCR (24, 27, 
32, 47), with only the targeted gene-specific primers varying (HE - (26, 44, 74), MP - (28), 
NS - (45), NP - (44)). A recent paper, by Salez et al. used nasal swabs from patients of all 
ages with acute respiratory symptoms to check for the presence of fluC (28). This was done 
using a TaqMan® real time RT-PCR looking for primers and probes on the matrix gene (28). 
There is, however, some discrepancy as to whether to use nasopharyngeal swabs or sputum 
samples to gain samples for detection of active fluC infections. Some papers state that 
sputum samples are better (79, 80), but not every patient can expectorate (particularly healthy 
participants) which would therefore suggest that nasopharyngeal swabs would be better, as 
every participant could provide a sample if they gave consent. It was also found in one of 
these papers that there was no significant difference between nasopharyngeal swab and 
sputum detection rates for fluA and fluB in culture or immunoassay (culture (P = 0.15), 
immunoassay (P = 0.07)) (79), which would also support the use of nasopharyngeal swabs 
over sputum samples. One study, by Kauppila et al. stated that despite analysing sputum 
samples, for future research they would recommend using an alternative such as nasal swabs 
or nasopharyngeal aspirates as in some cases they described it as “impossible” to collect 
sputum samples (27). 
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I.XII Staphylococcus aureus 
By analysing the swabs for the presence of S. aureus, it will prove that the swabs have made 
contact with the lining of the nares or nasopharynx and therefore that material has been 
collected on the swabs. 
Staphylococcus aureus (S. aureus) is a Gram-positive coccus from the genus Staphylococcus. 
Staphylococci were traditionally divided into two groups – those that were coagulase-positive 
and those that were coagulase-negative. The coagulase-positive Staphylococcus  group, 
which is able to clot blood plasma (via the coagulase reaction), is only comprised of  S. 
aureus and is thought to be more pathogenic than other Staphylococci (81), whereas the 
coagulase-negative Staphylococci are comprised of over 30 species (81).  
S. aureus, part of the natural flora, colonises the skin of humans and is most commonly found 
in the anterior nares (82).  People can be categorised into one of three groups: persistent 
carriers (approx. 20%), intermittent carriers (around 30%) and non-carriers (about 50%) (82). 
Criteria for classification into one of these groups varies between studies, but it can generally 
be accepted that a person would have all positive nasal swabs to be classed as ‘persistent’, at 
least one positive swab to be classed as ‘intermediate’ and no positive swabs to be classed as 
a non-carrier (82). General surveys of the population suggest nasal carriage rates of 35%, 
since 1934, (83) and of 27%,  since 2000 (82), which suggests a decrease in nasal carriage 
rates over time. Higher carriage rates were also found in men (84, 85) and newborn babies 
(86), with levels decreasing into adulthood (87). There is also a strong correlation between 
nasal carriage and hand carriage (88) – with hands being the main vector for transmission of 
S.aureus e.g. by nose picking (89). 
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I.XIII Deep Sequencing 
Deep sequencing is a process that allows the full genome of a virus, or similar, to be 
identified. Any nucleotide sequences in a given sample are detected, depending upon the 
quality of the sample provided  and the specific technique used (90). In the case of fluC, a 
high quality sample would enable the seven RNA segments to be isolated, and these data can 
then be analysed via metagenomics, the study of genomes collected from samples. This 
allows for greater understanding of the composition and behaviour of the viruses. For 
example, it allows for comparison between different strains of the virus and predictions as to 
which strains have evolved from others, as shown in the six different lineages in Figure 6. 
Phan et al. used metagenomics in the analysis of cyclovirus found in paediatric 
nasopharyngeal aspirates, which showed how metagenomics can be used to identify nucleic 
acids and indicate which viruses they are more closely related to (91). 
I.XIV Summary 
Influenza C is a respiratory virus which is currently under-researched and not well-
documented. Recent papers have suggested that the effects of infection with this virus are 
more severe than initially reported, particularly in younger children (46). 
There is a growing need for the importance of this virus to be outlined and its clinical 
significance to be described in further detail. Investigation of both patients and the general 
population will allow for further analysis of the fluC virus.  
Serum samples and nasal/nasopharyngeal swabs will show seropositivity levels and active 
fluC infections, respectively. 
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I.XV Aims  
This pilot study aims to identify the prevalence of fluC in the Lancaster area and also whether 
patients have previously been exposed to the fluC virus and therefore have antibodies against 
it.  
In order to achieve this, the following criteria will need to be met: 
 Nasopharyngeal and serum samples from patients of all ages with respiratory or ‘flu-
like’ symptoms will need to be collected, along with samples from asymptomatic 
participants. 
 A robust method for polymerase chain reaction (PCR) will need to be developed in 
order to process the nasopharyngeal swabs. 
 An appropriate enzyme-linked immunosorbent assay (ELISA) protocol will need to 
be produced to enable the serum samples to be analysed. 
 Any samples which are positive for fluC or may be deemed interesting will be sent for 
further deep sequencing at the Institute of Biological, Environmental and Rural 







II Materials and Methods 
II.I Materials 
II.I.I Polymerase chain reaction (PCR) materials 
 Nasopharyngeal swabs (MW951SENT, Sigma Virocult® ENT, Medical Wire) / 
Nasal swabs (Copan) 
 MagMAX™ Viral RNA Isolation Kit (Ambion) 
 High-Capacity RNA-to-cDNA™ Kit (Applied Biosystems®, Life Technologies™) 
 TaqMan® Environmental Master Mix 2.0 (Applied Biosystems®, Life 
Technologies™) 
 Positive control for qPCR (from Dr Nicolas Salez (Aix-Marseille Université)) 
 Primers and probe sequences for the matrix gene: 
o Forward: CAT AAT TGA ACT TGT CAA TGG TTT TGT 
o Reverse: TTC AGG CAT AAT TGT GGT CTT TAT ATC T 
o Probe: FAM-CTC GGC AGA TGG GAG AGA TGG TGT GTAMRA (28) 
II.I.II Enzyme-linked immunosorbent assay (ELISA) materials 
 Serum samples 
o Venous samples collected using a red-topped BD Vacutainer® serum tube 
10ml, Silica (Clot Activator)  
o Capillary samples collected using gold-topped BD Microtainer® Serum 
Separator Tubes (SST™) with added polymer gel  
 FluC Antigen, positive sera and negative sera (provided by Nicolas Salez)  
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II.II Ethical approval 
This study received a favourable opinion from NRES Committee London - Queen Square, 
reference: 14/LO/1634. 
The study has also been approved to be a part of the NIHR Clinical Research Network 
Portfolio: IRAS Project 147631, UKCRN ID 17799, Influenza C: a pilot study on a neglected 
respiratory virus. 
II.III Patient recruitment and sample collection 
Patients of all ages were recruited from the Royal Lancaster Infirmary (RLI), Lancaster, and 
Queen Square Medical Practice (QSMP), Lancaster. Additional samples were also provided 
by participants at Lancaster University. Seventy one samples were taken from patients with 
respiratory symptoms and a further 77 samples were taken from healthy ‘asymptomatic’ 
participants.  
II.III.I Inclusion criteria 
Any participants who were currently suffering from ‘Influenza like illness’ (defined as 
presence of one of the following: sudden onset of fever, nasal discharge, sore throat/cough, 
fatigue/body ache, difficulty in breathing (74)) were included in the symptomatic group. 
All patients included in the study were allocated a study number ranging from K001 – K148. 
II.III.II Consent 
Consent was provided by all participants with capacity over the age of 16. For those 
participants under the age of 16, parental consent was given in addition to the assent of the 
child. Any adult participants who lacked capacity for a transient period of time had a named 
consultee to give consent on their behalf, with the patient themselves asked to give their 
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consent in retrospect following regaining their decision-making capacity. If the patrticipant 
did not regain the ability to consent, then the consultee’s consent was taken on their behalf. 
II.III.III Samples 
Each participant had the option to consent to one, all, or none of the following samples: 
 A serum sample - for those over the age of 16.  
 A capillary blood sample – a heel prick for infants and a finger prick for older 
children (or adults, if venous sampling equipment wasn’t available).  
 A nasopharyngeal or nasal swab, depending upon the availability of swabs.  
Sample collection commenced in November 2014 and was completed in May 2015. A total 
of 148 samples were collected in this time; 71 symptomatic participants and 77 
asymptomatic. 
II.III.IV Serum sample preparation 
From all consenting adult participants, 10ml of venous blood was extracted using a red-
topped BD Vacutainer® tube. The blood samples were then left at room temperature to clot 
for around 15-30 minutes. The samples were then placed on ice for transportation to the 
laboratory where they were then centrifuged for 10 minutes at 1000-2000g (relative 
centrifugal force (g)) and 4°C. Once separated, the serum was extracted from the tube and 
placed into multiple anonymised Eppendorf tubes. Following this, the samples were then 
stored at -80oC until they were to be analysed. 
II.III.V Capillary sample preparation 
Patients under the age of 16 years, or adults who did not wish to provide a venous blood 
sample were able to provide a capillary blood sample instead. These samples were collected 
in gold-topped BD Microtainer® Serum Separator Tubes (SST™) with added polymer gel. 
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Once collected, the samples were allowed to clot for 30 minutes before being transported on 
ice to the laboratory. Following this, the tubes were placed into a centrifuge for at least 90 
seconds at 6000-15000g. The polymer barrier material within the tube then lies between the 
serum and blood cells, allowing the serum to be extracted as required. Samples were then 
placed in a freezer at-80oC until they were analysed. 
II.IV PCR  
II.IV.I RNA Isolation 
As the nasal swabs did not come with a preservative, an additional step had to be performed 
on the nasal swabs. The swab tips were immersed in 500µl PBS, and then were vortexed for 
around two minutes in order to mix the samples into the solution. The swab tips were then 
left suspended in the PBS until they were ready to be used for the RNA extraction. 
The MagMAX™ Viral RNA Isolation Kit (AM1939, Ambion®, Applied Biosystems™, Life 
Technologies™) was used to extract viral nucleic acids from all of the nasal/nasopharyngeal 
swab samples. The instructions provided by Applied Biosystems™ were followed, with 
400µl of sample used, resulting in a 50µl final volume, all of which were prepared in sterile 
1.5ml Eppendorf tubes. The carrier RNA that was supplied was replaced with linear 
acrylamide (5 mg/ml) (AM9520, Ambion®, Invitrogen™, Life Technologies™), in order to 
prevent the carrier RNA from masking any nucleotides in the samples. The same process was 
also followed using 400µl from an unused sterile swab, in order to act as a negative control.   
II.IV.II NanoDrop 
The quality and quantity of RNA extracted from samples was assessed by spectrophotometry 
using the NanoDrop
®
 1000 Spectrophotometer V3.3.0 (Thermo Fisher Scientific). The 
NanoDrop machine can generally accurately detect samples with a concentration above 
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2ng/µl, and so any sample with a value greater than two would be classed as having RNA.  
2µl of each sample was used in the spectrophotometer, and the remaining 48µl was then 
stored at -20oC.  
II.IV.III RNA to cDNA 
RNA was converted to cDNA using the High Capacity RNA-to-cDNA Kit (Applied 
Biosystems®, Life Technologies™), following the manufacturer’s instructions. Briefly, these 
were: 20.0µl reactions (9µl sample (RNA), 10µl 2X RT buffer, 1µl 20X RT enzyme mix) 
prepared in MicroAmp® 96-well Thin-Walled Reaction Plates (4346906, Life 
Technologies™). The plates were then centrifuged briefly to collect the contents at the 
bottom of the wells, before being placed into a Veriti® Thermal Cycler (4375786, Applied 
Biosystems®, Life Technologies™). The samples were incubated at 37oC for 60 minutes, 
before stopping the reaction at 95oC for 5 minutes and then holding at 4oC. Once completed, 
the plates were stored at -20oC. 
II.IV.IV PCR Optimisation 
Prior to analysing the samples, the qPCR was optimised using three different master mixes –
TaqMan® Gene Expression Master Mix, Universal Master Mix and TaqMan® 
Environmental Master Mix 2.0. The positive control (sent by Nicolas Salez - positive control 
for qPCR (100 µl at 28CT)), was supposed to have a cycle threshold (CT) value of 28, but all 
three master mixes gave a CT value over 30. The TaqMan® Environmental Master Mix 2.0 
gave the best CT value, and so was used for the qPCR. 
II.IV.V qPCR 
The primers and probe came in a preparation where they could not be immediately used and 
needed to be prepared. The probe had to be changed to a concentration of 2.5uM, and the 
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primers needed to be at a concentration of 5uM. These could then be stored and used in the 
qPCR.  
The cDNA samples were then prepared in MicroAmp® Optical 96-Well Reaction Plate 
(N8010560, Applied Biosystems™, Life Technologies™). Specific fluC primers and probes 
for the M gene were used (Forward primer: CAT AAT TGA ACT TGT CAA TGG TTT 
TGT; Reverse primer: TTC AGG CAT AAT TGT GGT CTT TAT ATC T; probe: FAM-
CTC GGC AGA TGG GAG AGA TGG TGT GTAMRA (28).) Each individual reaction was 
optimised for the primer and probe concentrations at a volume of 20.0µl (10μl of 2X 
TaqMan® Environmental Master Mix 2.0 (4396838, Applied Biosystems™, Life 
Technologies™), 2μl (500 nM) of each primer (Applied Biosystems™, Life 
Technologies™), 2μl (250 nM) of the probe (Applied Biosystems™, Life Technologies™) 
and 4μl DNA). For each plate positive and negative control (‘no template controls’) wells 
were also prepared, with the positive controls containing 4µl ‘positive control’, and the 
negative control containing 4μl of sterile PCR grade water (Sigma-Aldrich). The qPCR 
amplifications were then performed in a 7500 FAST Real-Time PCR system (Applied 
Biosystems®, Life Technologies™) with the thermo-cycling carried out at the following 
temperatures: one cycle of 95°C for 10 min and 45 cycles of 95°C for 15 s and 60°C for 1 
min.  
II.IV.VI Test for inhibition 
An inhibition test was performed to check that there was nothing in the samples which would 
prevent or inhibit amplification. Five samples were chosen, which had appeared negative 
following qPCR. Each reaction was at a volume of 30µl, and contained: 15µl 2X TaqMan® 
Environmental Master Mix 2.0 (4396838, Applied Biosystems™, Life Technologies™), 3µl 
(500 nM) of both primers (Applied Biosystems™, Life Technologies™), 3µl (250 nM) probe 
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(Applied Biosystems™, Life Technologies™), 4µl Sample DNA (sterile PCR grade water 
(Sigma-Aldrich) used for controls), 2µl Positive Control DNA. The same process was then 
followed as for the qPCR. 
II.V ELISA   
II.V.I Total IgG ELISA optimisation 
A direct ELISA was used with the intention of calculating the total IgG concentrations in the 
serum samples. In order to have reliable results, the ELISA protocol needed to be optimised. 
The method in section II.V.II was followed. Initially the sera were diluted at concentrations 
of 1:500 (2µl serum + 1ml carbonate buffer (CB)) and 1:1000, with the secondary antibody 
(ab6858, goat anti-human HRP, Abcam®) at a concentration of 1:2000 (1.0µg/ml in BB) and 
fish gelatine (2.5% (v/v) coldwater fish gelatine in 0.05% (v/v)) as the block. As these 
resulted in an excessively intense signal, the secondary antibody was tried at dilutions of 
1:2000 and 1:4000. Again these samples were too strong and different blocks were compared 
-   Marvel (1% w/v Marvel milk powder in PBST (0.05%)), fish gelatine and bovine serum 
albumin (BSA) (1% w/v BSA in PBS). As the plates still developed too quickly the 
SureBlue™ (TMB Microwell Peroxidase Substrate solution (KPL)) used was compared to 
SureBlue Reserve™ (TMB Microwell Peroxidase Substrate (1-Component)).  
Samples were then diluted to concentrations of 1:1000 and 1:4000; 1.10 000 and 1:20 000; 
1:250 000, 1:500 000 and 1: 1 000 000; and finally 1:104, 1:105, 1:106, 1:107, 1:108 and 1:109 
(over four different trials). Final results showed that the most successful combination was to 
use BSA as the blocking buffer, the secondary antibody at a concentration of 1:4000, and 
samples at dilutions of 1:100 000, 1:1 000 000 and 1:10 000 000. 
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II.V.II ELISA –Total IgG (Direct) 
In order to be able to fully interpret the levels of fluC IgG antibodies, the total IgG antibody 
levels were also calculated. 
Serum samples were diluted to three different concentrations in carbonate buffer (CB): 1:100 
000, 1:1 000 000, 1: 10 000 000. 
 1µl + 1000µl CB = 1:1000 (A) 
 10µl A + 990µl CB = 1:100 000 (B) 
 100µl B + 900µl CB = 1:1 000 000 (C) 
 100µl C + 900µl CB = 1:10 000 000 (D) 
Serum dilutions B, C and D were added to the plate in duplicate, allowing 10 samples to be 
analysed per plate. 
Twenty four wells were filled with twelve doubling dilutions of IgG standards in duplicate. 
Firstly, to make up the IgG curve standards, 5µl IgG (1mg/ml) was added to 2ml carbonate 
buffer to give the first standard (2.5µg/ml). One ml carbonate buffer was then added to 11 
more tubes, before adding 1ml of the previous IgG standard, creating 12 double dilution 
standards in carbonate buffer. 
The remaining twelve wells only had carbonate buffer added, allowing for any background 
absorbance to be monitored. 
100µl of each solution was added to each relevant well. The plate was then covered with 
Parafilm® and left to incubate overnight at 4oC. 
The following day the plate was sharply inverted to remove any excess unbound serum/IgG 
and blotted on blue paper to absorb any excess. The plate was then washed three times using 
PBST (0.05%) - 200µl/well. All wash stages were performed this way. 
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200µl blocking buffer (1% w/v BSA – 1g in 100ml PBS) was added to each well and left to 
incubate at 37oC for one hour. The plate was then sharply inverted and washed as stated 
above. 
Secondary antibody (Goat Anti-Human IgG (HRP), ab6858, Abcam®) was diluted to a 
concentration of 1:4000 in BB (2.5µl 2oantibody in10ml BB) and 100µl was added to each 
well before incubating again at 37oC for one hour. The plate was again sharply inverted and 
washed.  
100µl SureBlue™ TMB Microwell Peroxidase Substrate solution (KPL) was added to each 
well and left to incubate at room temperature for four minutes. 100µl stop solution (1.6% v/v 
H2SO4 solution in water) was added to each well and then finally the absorbance was 
measured at 450nM using a Wallac Victor2™ (Perkin Elmer) plate reader. 
In order to estimate the concentration of IgG in each sample, absorbance values were plotted 
on the IgG standard curves on each plate. A line was drawn along the ‘straight’ aspect of the 
curve, with values at concentrations of 0.078125µg (7.11, -log (concentration of IgG)) 
and0.002441µg (8.61) used on each graph to allow direct comparison between plates. The 
average background absorbance was detracted from each sample in order to remove any non-
specific contamination etc. Examples of the standard curves can be seen in Figures 12-15. 
II.V.III ELISA – Influenza C antibodies (Indirect) 
An ELISA was performed to detect antibodies in the patient’s bloodstream, showing that they 
have previously been exposed to fluC. The method used was a protocol provided by Nicolas 
Salez, who has previously done work on fluC (28). 
This method was also compared to a standard protocol used in our labs for detecting alpha 
haemolysin (AH) antibodies, but Salez’s protocol appeared to only work for fluC antibodies. 
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Maxisorp® Plates (Nunc ImmunoMaxiSorp® F96, Thermo Scientific) were coated using the 
fluC antigen diluted to a concentration of 1:400 in PBS. 100µl was added to each of the test 
and control wells. For the standard curve, doubling dilutions of the human IgG were 
prepared, starting at 2.5µg/ml (5µl IgG (1mg/ml) added to 2ml carbonate buffer). Twelve 
wells were coated with 100µl of the IgG standards in carbonate buffer. The plate was then 
covered in Parafilm and wrapped in foil to avoid the light, then incubated overnight at 4oC. 
The following day, each plate was sharply inverted to remove any unbound antigen or IgG 
and then tapped on blue paper roll in order to absorb any excess liquid. Following this, the 
plates were washed three times using 200µl PBST (phosphate buffered saline + tween 0.05%) 
per well. 
The next stage was to add the block; 200µl of the blocking buffer (1% Bovine Serum 
Albumin (BSA) in PBS) was added to each well, and then the plates were covered and 
incubated for two hours at 4oC. 
The plates were then washed again as outlined above. The serum samples were then prepared 
in a dilution of 1:400 in PBST + milk (2µl serum in 800µl PBST +milk 1%). One hundred µl 
of the diluted serum was then added to the relevant wells. Twelve wells (four wells of each 
serum) on each plate contained Sigma serum (H4522 Sigma, Human Serum from human 
male AB plasma, USA origin, sterile-filtered, Sigma-Aldrich®), positive control serum and 
negative control serum, also diluted to 1:400. At least six wells on each plate were used as 
‘background’ wells to enable the plate to be checked for any non-specific binding or 
contamination. The remaining wells had 100µl of PBST + milk added. Again the plates were 
covered and incubated for 45-50 minutes at 37oC. 
Following the incubation, the plates were washed again. The secondary antibody (Goat Anti-
Human IgG (HRP), ab6858, Abcam®) was prepared in PBST + milk to a dilution of 1:2000. 
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Per plate 10ml of PBST + milk was mixed with 5µl of the 2o antibody. This mixture was then 
added to each well in quantities of 100µl. The plates were then covered and incubated for a 
final time at 37oC for one hour. 
The plates were washed for a final time, before 100µl of SureBlue™ TMB Microwell 
Peroxidase Substrate solution (KPL) was added to each well. The plates were then left for 
four minutes, before adding 100µl of stop solution (1.6% v/v H2SO4 solution in water) to 
each well. Finally, the plates were read at 450nm for one second using a Wallac Victor2™ 
(Perkin Elmer) plate reader. 
All absorbance values had the average ‘background’ absorbance subtracted, in order to get a 
more accurate impression of the true absorbance. These values were then plotted on the 
standard curve for the relevant plate, to allow estimations of the IgG concentrations. The 
same points of reference (0.078125µg (7.11) and 0.002441µg (8.61)) were used on each 
curve to allow for comparison between plates. 
II.V.IV ELISA Sensitivity and specificity 
When compared to a virus neutralisation test, the ELISA protocol had a sensitivity of 66%, a 
specificity of 86% and a positive predictive value of 91% (28). This shows that for those 
samples that are classed as positive, they have a high probability of actually having fluC 
antibodies; however despite the high specificity and positive predictive values, the ELISA 
actually underestimates the number of positive samples and therefore the seroprevalence 
rates. 
II.V.V Analysis of positive and negative control sera 
The ELISA protocol in section II.V.II ‘ELISA –Total IgG (Direct)’ was also applied to both 
the positive and negative control sera, which allowed for a greater analysis and understanding 
of the control sera. 
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An ELISA following the protocol in section II.V.III ‘ELISA – Influenza C antibodies 
(Indirect)’ was also carried out comparing three different elements. The new antigen was 
tested at dilutions of 1:400 and 1:800, in order to confirm that both antigen preparations sent 
by Nicolas Salez were at the same concentration. The positive and negative controls and the 
Sigma serum were also applied to wells without the antigen to check for any non-specific 
binding. 
II.VI Agar Plates 
Agar plates were prepared to detect the presence of coagulase-positive S. aureus on the 
swabs. Baird-Parker Agar Base was dissolved into distilled water at a ratio of 58g BP /950ml 
distilled water. The solution was then autoclaved (at 121°C, 15psi, for 15minutes) to sterilise 
it. A Bunsen burner was lit to create an updraft and to help prevent any bacteria from falling 
into the prepared plates. Following this, the solution was then cooled to 50oC before adding 
the egg yolk (tellurite) emulsion, warmed to 50oC, at a ratio of 12.5ml egg yolk 
emulsion/250ml Baird-Parker. Once the plates had set, they were stored upside-down in the 
cold room until required. Each plate was streaked with a nasal/nasopharyngeal swab from a 
different participant, and then incubated at 37oC, again upside-down, for 24 to 48 hours. Any 
positive results appeared as grey/black in colour and had a clear halo around them. 
II.VII Deep Sequencing 
Any sample that appeared positive for fluC following PCR was prepared and sent to IBERS 
Phenomics Centre, Aberystwyth University, for deep sequencing. A selection of other 
samples were sent for deep sequencing to allow further analysis of the different types and 
groups of participants. Double-stranded cDNA was required for analysis, and this was 
prepared from the raw RNA extracted from the samples using the ‘SuperScript® Double-
Stranded cDNA Synthesis Kit’ (11917-010 Invitrogen™, Life Technologies™). For those 
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samples which were to be pooled for deep sequencing, the RNA in the samples was mixed 
prior to conversion to cDNA. 
Nine different Eppendorf tubes, labelled A – I, were sent for deep sequencing, with each 
Eppendorf tube containing a different variety of samples (see appendix 1).  
 A - Paediatric and symptomatic (lower RNA reading on NanoDrop) 
 B - Paediatric and symptomatic (higher RNA reading on NanoDrop) 
 C - Adult, high fluC IgG, symptomatic 
 D - Adult and fever 
 E - Asymptomatic, low total IgG 
 F - Asthmatics (higher fluC IgG) 
 G - COPD 
 H - Positive PCR 
 I - Positive PCR 




Various bioinformatics software was used in order to analyse all of the different samples.  
 NCBI Influenza Virus Resource (92) 
o Basic Local Alignment Search Tool (BLAST®) (93) 
 Artemis (Sanger Institute) (94) 
 Path-O-Gen v1.4 (95, 96) 
 Molecular Evolutionary Genetics Analysis (MEGA) 6.06 (97) 
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 Bayesian Evolutionary Analysis Utility (BEAUti) v1.8.0 (95) 
 Bayesian Evolutionary Analysis Sampling Trees (BEAST) v1.8.0 (95) 
 Tracer v1.6 (98) 
 TreeAnnotator v1.8.0 (95) 
 FigTree v.1.4.2 (99) 
The NCBI National Center for Biotechnology Information (NCBI) PubMed database (100) 
was also used as the basis for the literature review. 
II.VIII.II Phylogenetic trees 
Using the database GenBank (NIH genetic sequence database) (101) every fluC strain for 
each segment of the virus was downloaded (in FASTA format). These data were then able to 
be analysed using the bioinformatics software mentioned previously.  
Initially, every segment of the fluC virus was visualised using the Artemis software (94). 
The data were aligned by ClustaIW using MEGA (97), and any strains found in hosts other 
than humans were removed.  The best model was then determined using MEGA (97), before 
a ‘best fitting tree’ was created. 
In addition, the best fitting clock, R0 values and Bayesian skyline (102) were all analysed 
using the bioinformatics software mentioned previously. Path-O-Gen was used to check for 








III.I Recruitment summary 
Overall, 148 participants were recruited in the study. Figures 8-10 show the various groups 
present. 143 participants provided a nasal or nasopharyngeal swab (25 nasal, 118 
nasopharyngeal) and 129 participants gave a serum sample (101 venous, 28 capillary). 
 
Figure 8 – Gender of participants  
recruited  
69 males and 79 females were recruited into 
the study. 
 
Figure 9 – Symptomatic and asymptomatic 
participants recruited 
71 symptomatic and 77 asymptomatic 










































Figure 10 – Age of participants recruited 
More participants were recruited in the 20-29 and 50-59 age groups. Participants (n) were 
binned into 10-year spans of 0-9 (n=6), 10-19 (n=1), 20-29 (n=27), 30-39 (n=11), 40-49 

































Table 4 - Symptoms experienced by participants  
The most common symptoms described by ‘symptomatic’ participants: 











Chest pain (pleuritic) 11 
Nausea/vomiting 6 















III.II PCR results 
Two participants out of 148 (1.35%) were detected as positive for fluC via PCR. Those 
participants were K081 and K087, as shown in Figure 11. The samples contain the fluC 
cDNA and therefore, as each cycle completes, the genetic material increases, which is 
detected by the PCR machine, therefore giving off a signal. These two positive samples were 
then sent off for further deep sequencing. 
 
Figure 11 - PCR Amplification plot, plate 2  
The positive samples K081 and K087 and the positive control sample are shown. Each well 
containing a sample gives off a signal, shown in the Figure as a coloured line: row A - red 
line, row B - yellow line, row C - light green line, row D - dark green line, row E - light blue 
line, row F - dark blue line, row G - purple line, row H - pink line, as shown in the legend 
above. As each cycle completes, any samples containing fluC will increasingly contain more 
cDNA and therefore will give off a stronger signal. The positive control (pink/legend H) and 
sample K081 (yellow/legend B) both begin to increase from a cycle threshold (CT) value of 
around 34, and overlap slightly, whereas sample K087 (green/legend C) begins to increase 
nearer to 40 CT, and then all three exponentially increase for the remainder of the cycles. 
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III.III ELISA results 
As mentioned in section II.V.I ‘Total IgG ELISA optimisation’, several ELISAs were 
attempted in order to optimise the protocol for detection of total IgG antibodies, prior to 
testing the serum samples. Several different methods were trialled prior to finding a 
successful protocol. Initially the serum samples were tested at dilutions of 1:500 and 1:1000, 
with the secondary antibody diluted to 1:2000 and fish gelatine used as the block. These 
samples were far too strong and so the next method tried involved trialling the secondary 
antibody at two concentrations –1:2000, as before, and 1:4000. The serum samples were 
again left at concentrations of 1:500 and 1:1000 in order to keep all other elements the same. 
Again, all samples were still too strong and so, keeping all other constants the same, different 
blocks were tested; ‘Marvel’ milk powder, fish gelatine and BSA. Once again the samples 
developed too quickly, but appeared to be slightly more effective with BSA. It was then 
noted that SureBlue Reserve had been used to develop the plates, which is 50% more 
sensitive than SureBlue, and so the next plates tested compared SureBlue and SureBlue 
Reserve. Despite this, there wasn’t much difference between the plates and so the next step 
was to try diluting the samples further. The samples were diluted to 1:1000 and 1:4000 in the 
first trial and 1.10 000 and 1:20 000 in the second, all of which were still too strong. A paper 
was then found which tested total IgG levels in rat sera at a dilution of 1:200 000 (103) and 
so it became apparent that the samples were still at least 10 times too concentrated. The 
samples were then trialled at dilutions of 1:250 000, 1:500 000 and 1: 1 000 000 which gave 
better results, but most samples were still too strong. A specific ELISA for AH IgG 
antibodies was trialled at dilutions of 1:10, 1:100, 1:1000, 1:10 000 1:100 000 and 1:1 000 
000. Some AH IgG could still be detected at the weakest dilution, suggesting that the 
previous total IgG dilutions were still too strong. Finally the samples were tested at six 
different dilutions in order to get a full picture of what was going on. The dilutions used 
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were: 1:10 000, 1:100 000, 1:1 000 000, 1:10 000 000, 1:100 000 000 and 1:1 000 000 000.  
Samples around 1:1 000 000 fell nicely on the straight part of the curve, and so it seemed to 
be the best dilution to use. It was then decided to test all serum samples at dilutions of 1:100 
000, 1:1 000 000 and 1:10 000 000 in order to account for any samples which may have more 
or less IgG than expected. The block chosen was BSA and the secondary antibody was used 
at a concentration of 1:4000. A few mock ELISAs were also trialled in order to make sure 
that the standard curves were accurate, so that the IgG concentrations could be estimated in 
the samples. Once this process was complete, all of the serum samples were then tested so 
that a value could be calculated for the total IgG concentration of each participant. 
Optimising the protocol also allowed for perfecting pipetting skills etc., which can be 
demonstrated using concentration curves. An indirect ELISA protocol was also trialled 
testing for AH antibodies, as a practice for the fluC ELISA. Figures 12-15 show standard 
concentration curves taken from various ELISA plates. Figures 12 and 13 represent the IgG 
curves from a plates looking at total IgG concentrations, Figure 14 pictures an IgG curve 
from an AH IgG plate and Figure 15 shows a standard IgG curve from a fluC IgG plate. 
The curves each demonstrate doubling dilutions of known IgG concentrations, which when 
plotted on a graph shows the typical ‘sigmoid’ shape. These curves can then be used to 










 Figure 12 – Standard IgG Concentration Curve (26/3/15) - Total IgG Plate  
The standard IgG curve for the ELISA plate comparing serum sample total IgG 
concentrations of 1:250 000, 1:500 000 and 1:1 000 000 
Table 5 - ELISA results establishing total IgG concentrations (10/4/15) 
The results from the total IgG ELISA comparing serum samples at dilutions of 1:10 000, 
1:100 000, 1:1 000 000, 1:10 000 000, 1:100 000 000, and 1:1 000 000 000. These results 
were also repeated and confirmed. Red indicates high levels of IgG in a sample, and green 
indicates a low level of IgG. Each coloured cell indicates a well on the ELISA plate. The two 
rows of ‘curve’ wells contained samples with known levels of IgG, in doubling dilutions, 
which when plotted produces a standard IgG curve of known concentrations which allows for 




















-log (concentration of IgG)
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 (1:10 000) (1:100 000) (1:1 000 000) (1:10 000 000) (1:100 000 000) (1:1 000 000 000) 
Sigma* 2.767 2.702 2.707 2.698 2.227 2.170 0.713 0.792 0.194 0.173 0.860 0.728 
FBS* 0.077 0.075 0.079 0.071 0.080 0.083 0.074 0.061 0.069 0.077 0.068 0.063 
Serum* 
2.795 2.733 2.645 2.720 1.716 2.068 0.572 0.548 0.200 0.212 0.176 0.195 
2.735 2.740 2.481 2.399 1.078 1.047 0.384 0.268 0.132 0.161 0.116 0.125 
2.811 2.797 2.755 2.698 2.432 2.492 0.841 0.886 0.986 1.126 0.796 0.772 
Background 0.130 0.105 0.089 0.079 0.074 0.074 0.070 0.070 0.071 0.072 0.066 0.430 
Curve 2.811 2.869 2.790 2.764 2.715 2.748 2.711 2.747 2.690 2.580 2.495 2.423 
Curve 2.171 2.145 1.768 1.716 1.159 1.241 0.783 0.763 0.452 0.465 0.286 0.289 
*dilutions 1:10 000 - 1:1 000 000 000 (in duplicate), left to right  
 
Figure 13 - Standard IgG Concentration Curve (10/4/15) - Total IgG Plate 

























Figure 14 - Standard IgG Concentration Curve (21/4/15) - AH IgG Plate 
This is the standard IgG curve for one of the AH ELISA plates, looking for specific IgG 































Figure 15- Standard IgG Concentration Curve (21/4/15) - FluC IgG Plate 
This shows the standard IgG curve from a fluC IgG-specific ELISA plate. 
III.III.I Influenza C IgG antibody levels 
Table 6 (see appendix 2) shows the fluC IgG antibody results. Overall 106 serum samples 
were seropositive, and 23 samples were seronegative, giving a seropositivity of 82%. 
Estimates were based upon the standard IgG concentration curves for each plate, with the 
maximum and minimum values (0.078125µg (7.11) and 0.002441µg (8.61)) remaining the 
same for each plate. Any sample which had an absorbance value above the maximum point 
on the line had to be given as an estimate above a set value. The calculations used to 
determine whether a sample was positive or negative are shown in section ‘III.III.IV 
























Table 6 - Influenza C IgG Concentration (see appendix 2) 
Figures 16, 18 and 19 show the mean fluC IgG antibodies in various population groups.  The 
age distribution of fluC antibodies is shown in Figure 16, whereas Figure 18 compares the 
distribution of fluC IgG antibodies between different genders, and Figure 19 shows the 
distribution of IgG antibodies between the symptomatic and asymptomatic groups. There was 
little difference between the male and female participant IgG levels; however the 
symptomatic group had slightly higher levels of fluC IgG antibodies than the asymptomatic. 
Overall the variety of fluC IgG levels between the different age groups was small, with most 
age groups having similar levels of antibodies. The 10-19 years age group had lower levels of 
antibodies, but as there was only one participant in this group it is difficult to comment on. 
Figure 17 shows the age distribution of the mean fluC IgG antibodies in both the 
symptomatic and asymptomatic groups. 
 

























The number below the age group on the x axis indicates the number of participants in that 
group. No participants in the 0-9 years group provided a serum sample. The bars indicate the 
variance in the data for the age group. 
 
Figure 17 - Age distribution of fluC IgG antibodies - symptomatic vs. asymptomatic 
The red bars indicate the asymptomatic participants and the blue bars indicate the 
symptomatic participants. No participants in the 0-9 age group provided a serum sample. The 




























Figure 18 - Gender distribution of fluC IgG antibodies  
The mean IgG concentration for the male participants was 2.50mg.dl and the mean IgG 
concentration for the female participants was 2.31mg/dl, showing that there is not a great 
difference between the genders. The error bars indicate the variance in the data. 
 











































The mean IgG concentration for the symptomatic participants was 2.60mg.dl and the mean 
IgG concentration for the asymptomatic participants was 2.24mg/dl, which shows that despite 
the symptomatic participants have higher levels of fluC IgG antibodies, it is not greatly 
different from the asymptomatic participants. The error bars demonstrate the range of the 
data. 
III.III.II Antigen, positive and negative control serum tests 
Some additional tests were done on the antigen and positive and negative controls sent by 
Nicolas Salez (Aix-Marseille Université), in order to confirm exactly what the samples 
contained. 
The total IgG values for both serum samples were checked, to confirm that the negative 
serum was a true negative and not merely that the person who provided the sample was 
immunocompromised or had another similar problem. The values detected are in Table 7, 
which can be compared to those of the serum samples in Table 10. 
Table 7 - Total IgG Concentration in positive and negative controls 
This table shows the total IgG concentrations in mg/dl for the positive and negative control 
sera provided by Nicolas Salez. 
 Total IgG concentration (mg/dl) 
Positive control 1822.632 
Negative control 2047.266 
 
Two different antigen preparations were used for detecting the fluC antibodies. Both were 
sent by Nicolas Salez, but at different times, and so needed to be compared in order to prove 
that the samples had been analysed in the same manner. Tables 8 and 9 show the absorbance 
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values for the antigens when diluted to a concentration of 1:400, and the protocol outlined in 
section II.V.III ‘ELISA – Influenza C antibodies (Indirect)’ was followed.  
Table 8 - Old antigen absorbance (A450) values 
This table shows the mean absorbance (A450) values for the Sigma serum and positive and 
negative controls, when tested using the old antigen. The standard deviation (SD) and 
standard error (SE) are also shown. 
Old antigen 
Sigma Positive Negative
Mean 2.214 2.591 0.836 
SD 0.103 0.140 0.144 
SE 0.023 0.031 0.032 
 
Table 9 - New antigen absorbance (A450) values 
This table shows the mean absorbance (A450) values for the Sigma serum and positive and 
negative controls, when tested using the new antigen. The standard deviation (SD) and 
standard error (SE) are also shown. 
New antigen 
Sigma Positive Negative 
Mean 2.206 2.591 0.996 
SD 0.100 0.100 0.189 









Figure 20 - Comparison of absorbance values in old and new antigen  
Comparison of the absorbance values for the two different antigen preparations. The error 
bars show one standard deviation either side of the mean. The blue lines represent the old 
antigen and the red lines indicated the new antigen. The error bars show one standard 
deviation above and below the mean. 
A T test was also done to confirm whether the difference between the antigens was 
significant. When comparing the positive control sera and the Sigma serum (H4522 Sigma, 
Human Serum from human male AB plasma, USA origin, sterile-filtered, Sigma-Aldrich®), 
between the new and old antigens, the results were not significant at p<0.05. The negative 
control sera were, however, significantly different at p<0.05, but were not significant at 
p<0.01. 
III.III.III Total IgG antibody results 
Table 10 contains the total IgG antibody results for all of the serum samples. Again, estimates 



















plate (points at 0.078125µg (7.11) and 0.002441µg (8.61) used). Generally, values from the 
serum dilutions at 1:1 000 000 were used. Any samples which had particularly high 
absorbance values were plotted on the curve using the 1:10 000 000 dilution instead, to allow 
for more accurate calculations. Any participants that did not provide a serum sample were 
given a value of ‘-’ (these values were not included in any averages or statistics). The normal 
range for total IgG values were 639–1,349 mg/dl (54). Any values above this range were 
coloured red, and those below were coloured green. Overall, 71 samples were coloured red 
(above normal range), 22 samples were coloured green (below normal range), and the 
remaining 36 samples were coloured black i.e. within normal range. 
Table 10 - Total IgG antibody results (see appendix 3) 
 
Figures 21-23 show the distribution of the mean total IgG antibody levels in different 
population groups. Figure 21 shows the age distribution of total IgG antibodies, and it 
appears that most age groups have similar antibody levels. Although the 10-19 age group has 
a particularly low level and the 90-99 age group has a particularly high level, as only one 
participant was in each of these age groups these results cannot be relied upon. Figure 22 
compares the symptomatic and asymptomatic group total IgG levels and Figure 23 compares 
the total IgG levels between male and females, however all of these groups give very similar 




Figure 21 – Age distribution of total IgG antibodies 
No participants in the 0-9 years group provided a serum sample. The numbers on the x axis 
below the age group show the number of participants in each age group.  
 
Figure 22 – Comparison of total IgG antibodies in symptomatic and asymptomatic 
participants 
The mean total IgG level for the symptomatic participants was 1902.70mg/dl and for the 












































Figure 23 - Gender distribution of total IgG antibodies 
The mean total IgG level for the male participants was 2054.13mg/dl and for the female 
participants was 1941.30mg/dl. The error bars demonstrate the variance in the data. 
Table 11 - Comparison of FluC and Total IgG Antibodies (see appendix 4) 
Table 11 compares the fluC and total IgG antibodies for each serum sample. 
III.III.IV Statistics 
In order to determine the cut-off values for positive and negative fluC antibody results, the 
values had to be analysed. As the antigen and positive and negative control sera were the 
same as used in the paper by Salez et al.(28) the data from this study were able to be directly 
compared with that in France. Every one of the French plates determined whether a sample 
was positive or negative using the same formula. All of the negative sera were averaged and 
then 2 standard deviations (SD) were added to the negative sera mean, with any samples that 
were above this value being classed as positive. In order to do so the plates needed to be 
‘normalised’ to the Marseille plate, which was used as the standard for Salez’s work. To do 
this, the following equation was used:   






















where A= 0.1037, b=Positive control, a= Negative control, N= 1.1011, and ‘OD raw’ is the 
raw optical density (OD)/absorbance value. Certain values remained constant between the 
different plates (A and N), whereas others varied to allow for the different conditions of the 
plates (a, OD raw and b). Any sample with a value >0.733 was classed as positive (In Salez’s 
paper, a value >0.797 was classed as positive (28)). As there was the same standard positive 
value for all plates, an OD value may give a positive sample on one plate and a negative on 
another, due to the different values used in the formula. Figure 24 shows the positive and 
negative samples using this equation and plotting these values against age.  
 
Figure 24 – Age distribution of positive and negative serum samples, as calculated by 
Salez’s formula 
Blue indicates a positive sample (>0.733), of which there were 106 samples, and red indicates 
a negative sample (<0.733), of which there were 23 samples. 
An alternative method was also trialled to calculate positive and negative samples. It is 
defined that 95% of the data falls within 1.96 SD of the mean. This basis was used to decide 





















SD of the positive control mean was classed as positive, and any sample which fell within 
1.96SD of the negative control mean was classed as negative, and all the others were classed 
as ‘in-between’. This would give a positive control mean of 4.46 mg/dl (1.45-7.47mg/dl).  
Figure 25 and Table 12 show the mean fluC IgG concentrations for the positive and negative 
controls and also the Sigma serum. Error bars show one standard deviation either side of the 
mean. Figure 26 shows how the samples would be classified if this method was used. 
 
Figure 25 - Positive and negative control serum - FluC IgG concentrations 
The blue lines indicate the old antigen, the red lines indicate the new antigen and the green 
line represents the mean of the old and new antigens. The error bars show one standard 
deviation either side of the mean. 
Table 12 - Positive and negative control serum - FluC IgG concentrations 
The mean fluC IgG concentrations (mg/dl) were calculated for the positive and negative sera 





























calculated, and 1.96SD was both added and subtracted to the mean for each serum, in order to 
get an estimation of where 95% of the data should lie. 
Combined antigen 
Sigma Positive Negative 
Mean 2.240 4.459 0.247 
SD 0.592 1.536 0.099 
SE 0.224 0.580 0.037 
Mean 
+1.96SD 
3.401 7.469 0.440 
Mean -
1.96SD 
1.079 1.449 0.053 
 
 
Figure 26 - Age distribution of positive and negative serum samples, as calculated by 
using 1.96 SD 
This figure represents the data shown in Table 12. The positive samples (>1.449) are 
coloured blue, the negative samples (<0.440) are coloured red and the remaining samples in 
between the positive and negative regions are coloured green. This shows that 99 samples are 






















Table 13 - Chi square test - Male and Female, Symptomatic and Asymptomatic 
This table shows the total number of male and female symptomatic and asymptomatic 
participants. A chi square test was then performed on this data. 
Symptomatic Asymptomatic Total 
Male 25 36 61 
Female 32 36 68 
Total 57 72 129 
The x2 value for the chi square test was 0.481221, which shows that the probability of a large 
value of x2 falls between 0.50 and 0.25. This means that the data can be considered to be 
randomised with respect to gender and clinical status. 
In order to further analyse the data for any statistically significant differences, either T tests 
or Mann Whitney U tests needed to be used, based upon whether the data are normally 



























Age (years)0   1   21     6      15          19       16        13          9              1       
77 
 
Figure 27 - FluC seropositivity in comparison to age 
Due to the low number of participants in the 0-9, 10-19 and 90-99 groups, the results cannot 
be relied upon. The numbers below each of the groups on the x axis represents the number of 
participants in that group. Overall the figure shows the absence of a bell-shaped curve, and 
therefore indicates the data are not normally distributed and are therefore non parametric. 
Due to this, the data should be further analysed via Mann Whitney U tests.  
Six different Mann Whitney U tests were done to fully compare the different groups. The 
comparisons were: male asymptomatic and female asymptomatic fluC IgG antibody levels; 
male symptomatic and female symptomatic fluC IgG antibody levels; male asymptomatic 
and female asymptomatic total IgG antibody levels; male symptomatic and female 
symptomatic total IgG antibody levels; symptomatic and asymptomatic fluC IgG antibody 




Figure 28 – Mean FluC and Total IgG Antibody levels for different population groups  
A-f above compare the mean IgG levels for each group, with error bars added showing the 
variance of the data, via one standard deviation above and below the mean. a) Male control 
and female asymptomatic fluC IgG antibody levels. Blue indicates male asymptomatic and 
red indicates female asymptomatic. b) Male symptomatic and female symptomatic fluC IgG 
antibody levels. Blue indicates male symptomatic and red indicates female symptomatic. c) 
Male asymptomatic and female asymptomatic total IgG antibody levels. Blue indicates male 













































































































































































symptomatic total IgG antibody levels. Blue indicates male symptomatic and red indicates 
female symptomatic. e) Symptomatic and asymptomatic fluC IgG antibody levels. Blue 
indicates symptomatic and red indicates asymptomatic. This is the only set of results which is 
significantly different. f) Symptomatic and asymptomatic total IgG antibody levels. Blue 
indicates symptomatic and red indicates asymptomatic 
Table 14 - Mann Whitney U Test 
This table shows the z value results for each of the six groups analysed using the Mann 
Whitney U tests. The calculated z values were analysed using a standard table of z values in 
order to determine which groups were statistically significant, and if so at what parameters. 
There is only one significant test – the symptomatic fluC IgG levels and the asymptomatic 
fluC IgG levels (p<0.05).  
Control Experimental Z value Significant? 
Male Asymptomatic Flu C 
IgG 
Female Asymptomatic 
Flu C IgG 
0.608164 
Not significant 
Male Symptomatic Flu C IgG 
Female Symptomatic 
Flu C IgG 
0.498532 
Not significant 










Symptomatic Flu C IgG 
Asymptomatic Flu C 
IgG 
2.205303 
Significant at P<0.05, 
not significant at 
P<0.01 









III.IV Plate results 
Table 15 shows the overall Staphylococcus plate results for all of the nasal and 
nasopharyngeal swab samples. ‘N/A’ indicates either that the participant did not provide a 
swab sample or that the swab was not streaked onto a Staphylococcus selective plate. 
Samples that grew bacteria were indicated as Staphylococcus present, and those which 
developed a clear halo around the bacterial colonies were marked as coagulase positive, 
therefore indicating that the bacteria are Staphylococcus aureus. 
Table 15 - Staphylococcus plate results (see appendix 5) 
Overall 91 swabs were positive for S. aureus, 37 swabs were positive for other forms of 
Staphylococcus and 12 swabs were negative. 
Tables 16-22 show the Staphylococcus plate results for different population groups. 
Table 16 - Staphylococcus plate results summary 
 
Staphylococcus 






 Positive 91 0 91 
Negative 37 12 49 
Total 128 12 140 
Total percentage Staphylococcus coagulase positive = 65% (S. aureus positive) 










 Positive 40 0 40 
Negative 20 6 26 
Total 60 6 66 
Total percentage Staphylococcus coagulase positive = 61% 
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 Positive 51 0 51 
Negative 17 6 23 
Total 68 6 74 
Total percentage Staphylococcus coagulase positive = 69% 










 Positive 74 0 74 
Negative 30 11 41 
Total 104 11 115 
Total percentage Staphylococcus coagulase positive = 64% 










 Positive 17 0 17 
Negative 7 1 8 
Total 24 1 25 

















 Positive 40 0 40 
Negative 22 12 34 
Total 62 12 74 
Total percentage Staphylococcus coagulase positive = 54% 










 Positive 51 0 51 
Negative 15 0 15 
Total 66 0 66 
Total percentage Staphylococcus coagulase positive = 77% 
III.V Bioinformatics and phylogenetic analysis 
III.V.I Reproduction values 
Reproduction values, or basic reproduction numbers (R), can be used to estimate how 
contagious a virus is. At a time of ‘0’, the R0 value for a specific virus will demonstrate how 
many other hosts the infected host can expect to infect from that point onwards. For example 
an R0 value of ‘2’ would indicate that an infected individual would be expected to infect two 
people. The R values of all three influenza viruses were analysed using the BEAST (Bayesian 
Evolutionary Analysis Sampling Trees) software package v1.8.0 (95) and Tracer software 
v1.6 (98). In order to calculate these data, all of the available fluC strains for each segment 
were downloaded in ‘FASTA’ format from the NCBI Influenza Virus Resource (92), before 
being aligned by ‘ClustalW’ in the MEGA software programme (97). Using these aligned 
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strains the best model was then determined using MEGA, before transferring the results to 
other bioinformatics software. Finally, using the software, the best clock was determined for 
each segment and all of the calculated data was then entered into BEAST and Tracer software 
packages in order to produce the R0 values.  
Table 23 – FluC R0 values, with best fitting model and clock  
This table shows the R0 values for each of the seven segments, as calculated using the best 
model and clock for each specific segment. Each segment was run in the software to 
determine which model and clock was the most appropriate for that segment. In order to 
accurately calculate the R0 value for a segment, the appropriate model and clock for that 
segment needed to be used. The exponential (exp) and logarithmic (log) clocks are both 
relaxed clock models, as opposed to strict. The substitution models of best fit are either the 
general time-reversible model (GTR) or the Tamura-Nei, 93 model (TN93). 
FluC segment Model Clock R0 values 
PB2 TN93 exp 1.029 
PB1 GTR exp 1.031 
P3 TN93 exp 1.031 
HE GTR log 1.486 
MP GTR log 1.068 
NP TN93 exp 1.101 
NS GTR exp 1.033 
 
This process was then applied to available fluA and fluB segments for comparison, and as 
mentioned previously, fluC is more closely related to fluB than fluA, and so it was to be 
expected that their R0 values would be similar. Table 24 shows the R0 value results for all of 
the segments for fluA, fluB and fluC. The data for fluB and C are both from human host 
populations, whereas the fluA data are from an avian host population. The mean R0 values 
are as follows: fluA – 2.15, fluB – 1.17 and fluC - 1.11. As  fluA has an R0 value around 
twice as large as the R0 values for fluB and fluC, it shows that fluA is the most contagious 
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virus, and almost twice as contagious as fluB and fluC. FluB appears to be slightly more 
contagious than fluC, but overall the two viruses have very similar values.  
Table 24 - R0 values – fluA, fluB and fluC 
This table shows the R0 value for each of the segments of the fluA, fluB and fluC viruses. 
The mean and standard deviation values are also shown. Overall fluA has the highest average 
R0 value – 2.15 
 R0 value 
Influenza virus A B C 





PB2 2.21 1.16 1.03 
PB1 2.29 1.12 1.03 
PA/P3 2.29 1.14 1.03 
HA/HE 2.02 1.07 1.49 
NP 2.27 1.11 1.07 
NA 2.36 1.12 - 
M1 1.50 1.46 1.10 
NS 
NS1 2.39 1.11 
1.03 
NS2 2.00 1.26 
Mean 2.15 1.17 1.11 
Standard deviation (SD) 0.28 0.12 0.17 
Lower range 1.87 1.06 0.94 
Upper range 2.42 1.29 1.28 
No. of values within 1 SD 8 9 6 
Total no. of values 9 9 7 
 
III.V.II Phylogenetic trees 
Using various bioinformatics software, phylogenetic trees have been created for all seven 
segments of the fluC virus. All of the available strains in the NCBI Influenza Virus Database 
(92)/GenBank (101) were downloaded and all full genome segments were used to construct 
the trees. The phylogenetic trees allow for comparison between the different strains of the 
virus, so that conclusions can be drawn as to which strains are more closely related and which 
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strains have evolved from which others. Figures 29- 35 show the phylogenetic trees for each 
of the seven segments. The ‘x axis’ under each tree represents time and the point on the left 
of the tree represents a fixed point in time from which all of the various strains have evolved. 
























Figure 29 - Phylogenetic tree of fluC HE segment  
This phylogenetic tree was created using the MEGA(97) and BEAST(95) software packages 
and was visualised using the FigTree software within BEAST (99). The ‘x axis’ represents 
time and the point on the left of the tree represents a fixed point in time from which all of the 
various strains have evolved. The tree prior used to create the tree was coalescent constant 
size.  
The various branches have been colour coded in order to allow for comparison to Figure 6 by 
Matsuzaki  et al. 2003) (31), reproduced overleaf. Each colour represents either one of the six 
lineages shown in Figure 6 - Taylor/47 (red), Kanagawa/1/76 (KA176) (green), 
Yamagata/26/81 (YA2681) (blue), Aichi/1/81 (AI181) (orange), Sao Paulo/378/82 (SP82) 
(yellow), and Mississippi/80 (MS80) (purple) or if the strain is a new strain, which has been 
found after Figure 6 was produced, then it has been coloured pink. 
The Taylor/47 lineage contains both the Taylor/47 and Ann Arbor/50 strains, both of which 
can be seen in adjacent branches of Figure 29, in the second cluster from the top of the tree. 
Some of the strains from the Aichi/1/81 lineage can be seen along the bottom branches of 
Figure 29, such as Georgia/69 and Johannesburg/67, but some of the branches are also 
clustered towards the top branches of the tree.  The Sao Paulo/82 lineage is also clearly 
visible as an isolated branch on the top right of the figure, however despite all three strains 
from this lineage being in the top half of the tree, they are not very well clustered. Again, the 
Yamagata/81 lineage is visible in Figure 29 below that of Taylor/47, but it is possible that 
these two lineages are not as clearly distinct in Figure 29 as they are in Figure 6. The 
Yamagata/81 lineage originally contained the most strains on the original Matsuzaki tree, and 
although this is still the case in this phylogenetic tree, the branches appear far more diverse. 
The remaining two lineages – Kanagawa/76 and Mississippi/80 – are not as clearly visible. 
Two of the strains within the Mississippi lineage Greece/79 and Nara/85 are in different 
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clusters of branches in Figure 29, suggesting that the phylogenetic tree in Figure 29 does not 
have as strong a suggestion of the six lineages present in Figure 6. All of the remaining 
strains coloured in pink are ‘new’ strains that were not available when Figure 6 was created. 












Figure 31 - Phylogenetic tree of fluC MP segment 
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Figure 32 - Phylogenetic tree of fluC NP segment 
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Figure 33 - Phylogenetic tree of fluC NS segment 
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Figure 34 - Phylogenetic tree of fluC P3 segment 
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Figure 35 - Phylogenetic tree of fluC PB1 segment 
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Figure 36 - Phylogenetic tree of fluC PB2 segment 
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The main aims of this research were to determine whether the fluC virus is prevalent in 
Lancaster and whether the general population have antibodies against the virus. In order to 
meet these aims, serum samples and nasal/nasopharyngeal swab samples had to be collected 
and analysed using PCRs and ELISAs. All data then had to be analysed statistically and 
compared to current literature in order to be able to draw conclusions about the significance 
of the work and results. 
IV.I PCR 
Despite there already being set PCR protocols and primers created for the detection of fluC, 
various issues arose throughout various stages of the PCR process. Firstly when isolating the 
RNA, it became apparent when looking at the NanoDrop (ND) results that the carrier RNA 
supplied with the kit could potentially be masking any RNA isolated from the samples. In 
order to rectify this, linear acrylamide was purchased and was used in direct replacement of 
the carrier RNA. 
When checking ND values for the samples there were also issues raised about the quality of 
the samples and whether any RNA had been extracted. Initially the ‘blank’ control sample 
used was water, which resulted in some samples obtaining a negative ND value. The blank 
reference value was then changed to a blank swab (a sterile swab which had been put through 
the same RNA extraction process), which gave better RNA values. Despite this, some ND 
values were still negative; however ND values ranged from -8.0 to 118.5 ng/µl. According to 
the manufacturer’s instructions, the machine can accurately detect RNA in samples above 2 
ng/µl, but as 37 samples had a negative ND value, it seems unlikely that these values can be 
relied upon. The positive control was also analysed via ND, and came out with a value of -32 
ng/µl, the lowest value out of all of the samples. As it has been proven that this sample works 
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during PCR and therefore contains RNA, it also supports the view that the ND scores aren’t 
reliable. 
Another issue during the RNA extraction phase was caused by the nasal swabs (Copan). 
These swabs came with a sponge for transportation and preservation rather than a solution. 
As the nasopharyngeal swabs came with a viral transport medium, the solution could then be 
used immediately with the RNA isolation kit. As the nasal swabs did not, the samples had to 
be resuspended in solution in order to extract the sample from the swab tip.  
In order to have the best chance of detecting any positive samples, the PCR had to be 
optimised. Performing the qPCR required the use of a master mix, and so the TaqMan® Gene 
Expression Master Mix (Applied Biosystems®, Life Technologies™) was purchased. The 
positive control provided by Nicolas Salez was claimed to have a CT value of 28, however 
when tested using the Gene Expression Master Mix this was not the case. A second qPCR 
was then trialled using this master mix and comparing it to a ‘Universal Master Mix’ that was 
already in the lab. The universal master mix gave a better CT value and so the samples were 
initially analysed using this master mix. After testing two full plates of samples, there were 
no positive results and some strange artefacts on the readings, and so an inhibition test was 
performed. The inhibition test showed the positive control samples to have worked, but some 
samples gave higher positive readings than the positive control. This would suggest that there 
is no inhibiting factor in the master mix or other element of the solution and would also 
appear as if some of the samples may have either been positive or something in the mixture 
actually facilitates the reaction. As they results were slightly inconclusive it was decided that 
a third master mix would be tested to see if that provided more reliable results.  
A test qPCR was run comparing the Universal Master Mix with the TaqMan® Environmental 
Master Mix (EMM). The EMM gave a lower CT value and so it was decided to use the EMM 
to test the samples. The ambiguous samples that were previously tested were repeated; the 
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positive and negative controls worked well and the artefacts were no longer present on the 
results, showing that the plate had now worked. The remaining samples were also analysed 
and it was found that two samples came up positive, as shown in Figure 11.  
IV.I.I FluC prevalence 
Out of 148 nasal and nasopharyngeal swab samples tested, two samples (1.35%) were 
detected as being positive via PCR. It was expected that any positive samples would appear 
in participants who had typical ‘flu’ symptoms, or those with symptoms that have previously 
been described in a fluC infection. Surprisingly, both positive samples were found in 
asymptomatic patients who claimed that they were asymptomatic. This could be due to a 
number of reasons; perhaps the participants simply had strong immune systems and were 
therefore asymptomatic, or the strain that they were infected with was mild and so they had 
not chosen to complain about their symptoms. The participants could also currently be in the 
incubation stage of the virus and although were carrying the virus were yet to exhibit 
symptoms. In contrast to this, they could have been recovering from a recent infection and 
failed to mention when asked that they had had a recent infection and were therefore included 
in the asymptomatic group.  
As the positive samples were collected from potentially asymptomatic carriers, it is therefore 
difficult to compare the statistics in this study to those found in other studies. Other papers 
have found positive results in symptomatic patients and have been able to compare symptoms 
etc. and other clinical factors, but that is not possible in this case. 
When looking back at the data, both positive swabs were collected a day apart at the end of 
January 2015. This matches with most other papers, which suggest that the peak season for 
fluC is January-June (23, 25-27, 29-35). The first samples were collected in November 2014 
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and the very last sample was collected in May 2015, however the majority of samples were 
collected in January (93 samples) and February (39 samples) 2015. 
IV.I.II Deep sequencing 
One of the large decisions to make was which samples were to be sent for deep sequencing. 
Ideally, the samples sent needed to optimise the chance of finding a positive fluC sample in 
case any were missed via PCR. The samples sent also needed to be varied enough that 
comparisons could potentially be made between groups of samples. Originally four mixtures 
were sent – one containing the paediatric samples, one containing symptomatic adult samples 
with high fluC IgG levels, another contained all of the samples from adults with pyrexia and 
finally there was an asymptomatic group containing asymptomatic adult samples with low 
IgG levels. 
Unfortunately it was found that the samples that had been sent were single-stranded cDNA, 
rather than the double-stranded cDNA required for the deep sequencing. During this time two 
samples had also appeared positive on PCR and so needed to also be sent for deep 
sequencing. 
A new cDNA synthesis kit was ordered which produced double-stranded cDNA; however 
this could only convert a maximum of 10 RNA samples to cDNA (and also required the 
purchase of the oligo (dT) primer which delayed matters further). It was decided to send nine 
samples for deep sequencing; however for some of these samples the RNA was pooled prior 
to conversion to cDNA in order to increase the diversity in the samples. Nine new groups 
were chosen (see section II.VII), with the aim being to create as vast a difference between the 
samples as possible, whilst still aiming to optimise the chances of retrieving fluC sequences. 
As fluC is a respiratory virus, the addition of the ‘asthma’ and COPD groups will allow for a 
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greater analysis of the impact of the virus, once the deep sequencing results have been 
returned. 
IV.II Total IgG ELISA 
Prior to testing the serum samples, the ELISA had to be optimised and several different 
methods were trialled prior to finding a successful protocol.  
From all of the total IgG serum results, the mean was 1994.66 mg/dl (range 293.39- 5504.65 
mg/dl). This is significantly higher than the reference values used of 994 mg/dl (639–1,349) 
(53, 54). This could be due to the estimation of the IgG levels by plotting them on the curves. 
The method is not exact as the curve is produced by using a slightly different method to the 
samples. There is also some discrepancy when choosing which points to use to draw the 
‘straight’ aspect of the curve; the points are chosen by eye, based upon the viewer’s opinion 
as to where the straight line starts. This could potentially mean two different people could 
choose different points to base the straight line on, therefore giving different results. This 
may help to partially explain why the total IgG levels found in this study are much more 
variable than in the literature. As the same process was used to determine fluC IgG levels, 
then the total IgG values still serve a purpose as they allow for  a basic comparison between 
samples, and the total IgG values can also be used to check samples for any 
immunosuppression etc.. According to the literature, a few of the samples in this study would 
be classed as having an IgG deficiency (55, 56), but as stated by Puissant-Lubrano et al. 
many of their patients with decreased levels of IgG were actually healthy (56), and so it is 
difficult to draw conclusions on the participants in this study.  
IV.III FluC IgG ELISA 
In order to make sure the protocol sent by Salez would work, it was trialled and compared to 
a standard protocol already in use at Lancaster University for AH-specific IgG. The 
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university protocol worked well, however Salez’s protocol did not work when applied to AH. 
As limited reagents were sent, the protocol could not be practiced too much as it risked using 
up the sera etc. The Lancaster protocol was practised, but adapted to be as close to Salez’s 
protocol as possible, and was then applied to every venous serum sample to give an AH IgG 
OD value. A plate was then trialled following Salez’s protocol exactly and testing only a 
couple of samples. This was successful, suggesting that the ELISA is very specific for fluC, 
and so all of the samples were then able to be tested. 
IV.III.I FluC antibodies 
As a similar study had not been carried out in this area before, there was uncertainty as to 
whether the general population would have antibodies to the virus, particularly as there has 
rarely been any documentation of fluC in the UK. The levels of seropositivity were higher 
than expected, but show that the fluC virus is in the area and that the study was worthwhile.  
The mean fluC IgG concentration was 2.40 mg/dl (range 0.24 mg/dl – 5.88 mg/dl), which is 
around 10 times lower than that listed for fluA (24 mg/dl (range 15 – 39 mg/dl) (55)). This 
could be due to a number of reasons, the main one being that they are different viruses and it 
would be expected that fluA is far more prevalent, however different populations and 
detection techniques will also impact on the final values. 
Statistics for the UK seroprevalence rates are around 60-70% (28, 70), and although the 
values from this study are slightly higher than may be expected, they are still in keeping with 
worldwide statistics (23, 27, 28, 32, 35). There are also discrepancies as to how to decide 
which samples to class as positive and negative. Using the original method of 1.96SD gave a 
seropositivity rate of 77%. This value, although slightly lower, supports the seropositivity 
rate calculated above and uses a similar method to Salez.  
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In order to be able to analyse the results between the different population groups, statistical 
tests were applied to the data. A chi square test was performed, comparing the male and 
female symptomatic and asymptomatic groups, and the seropositive results were compared to 
age, which showed that the data were both randomly allocated and not normally distributed. 
This then meant that the data had to be analysed using Mann Whitney U tests. Six different 
Mann Whitney U tests were then performed comparing six different groups of data; male and 
female asymptomatic fluC IgG, male and female symptomatic fluC IgG, male and female 
asymptomatic total IgG, symptomatic male and female total IgG, symptomatic and 
asymptomatic fluC IgG and symptomatic and asymptomatic total IgG. The only test which 
was significantly different at p<0.05 was the comparison between the symptomatic and 
asymptomatic and fluC IgG levels, which shows that the symptomatic participants have 
statistically significant higher levels of fluC IgG antibodies. This also shows that there is no 
difference between the male and female groups in any test and that the symptomatic and 
asymptomatic groups do not have significantly different total IgG levels.  
IV.III.II Determining positive and negative serum samples 
One area of discrepancy was the method used to determine which serum samples to class as 
positive and negative. Although every paper that performs ELISAs for this purpose must use 
a specific method or calculation, there is often no mention of this in the published articles. 
It is statistically accepted that 95% of the data falls within 1.96 standard deviations (SD) of 
the mean. Based upon this principal, originally the data which fell within 1.96SD of the 
positive control mean were classed as positive, and those which fell within 1.96SD of the 
negative control mean were classed as negative. This gave a seropositivity rate of 77% which, 
although in keeping with the current literature, left 26 samples in a ‘grey area’ between the 
two groups of positive and negative samples.  
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A paper was then found testing serum samples via ELISA IgG antibodies to the Ebola virus 
(104). Although looking at a different virus, the principals were still the same and so their 
method was used to determine which samples to class as positive. Any sample which had an 
optical density value greater than 3SD above the mean negative control was classed as 
positive (104), which when applied to this data made only five samples out of 129 negative, 
giving a seropositivity rate of 96%. This figure is higher than all of the values in the literature 
and so may be unreliable. 
The alternative method used was to compare our samples to those analysed by Salez et al. As 
the antigen and positive and negative control sera used in this study was provided by Salez, it 
was justifiable to compare the data from this study to that study. Salez worked out the mean 
of the negative sera and then calculated 2SD above and below the mean. Any samples which 
fell within this range were classed as negative and all other samples were classed as positive. 
As they collected and analysed samples in a variety of places, all of their samples were 
compared to the ‘control’ plate in Marseille, which was also done to the samples from this 
study. Using this calculation gave a seropositivity rate of 82% for this data. 
IV.III.III Analysis of the products provided by Salez 
In order to make sure that the negative control was a true negative, and not just an IgG 
depleted sample, such as from an immunocompromised patient, the total IgG level needed to 
be quantified.  The results are shown in Table 7 - the positive serum had a total IgG 
concentration of 1822.63 mg/dl and the negative control had a concentration of 2047.27 
mg/dl. As the mean total IgG concentration for all of the serum samples was 1994.66 mg/dl, 
this shows that both the positive and negative control sera have normal IgG levels. This then 
proves that the fluC ELISA is looking for specific IgG antibodies, and is not simply testing 
overall IgG concentrations. 
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Part way through the testing of the serum samples the initial antigen solution ran out and so a 
second solution had to be used. In order to confirm that these two antigen solutions were the 
same, they had to be compared. To do this, the new antigen was diluted to concentrations of 
both 1:400 and 1:800. The OD values for the Sigma serum and the positive and negative 
controls were read and compared to those for the old antigen. The results were then plotted 
on a graph in order to provide a visual representation (Figure 25). As this graph shows, both 
antigens give very similar OD results, and as the T tests showed, one can be confident that 
there is not a statistical difference between the two antigen solutions. The values at 1:800 
were almost exactly at the expected values, around half of those at 1:400, which again shows 
the reliability of the results.  
It was also noted that the negative control serum did not give an OD value of ‘0’, which some 
might expect would be the definition of a truly negative sample. A final test was carried out 
on the control sera to check whether the sera would stick to the wells in the plate, regardless 
of the presence of the antigen, which may explain the reasoning behind the raised negative 
value.  The negative control serum gave a higher OD reading (0.245), when there was no 
antigen present, than both the positive control serum (0.177) and the background wells 
(0.108). This does then appear to partially explain the ‘raised’ negative control readings. 
IV.IV Screening of swabs for Staphylococci 
All of the swabs were streaked onto S. aureus selective plates in order to prove that the swabs 
had made contact with the lining of the nostril or nasopharynx. One hundred and forty out of 
the 143 samples collected were tested, as the first three swabs were collected prior to 
obtaining the material needed to pour the plates. Overall 91% of the swabs grew some form 
of Staphylococcus and 65% of the swabs were coagulase positive, confirming the presence of 
S.aureus. There were coagulase positive samples in all age groups – the youngest was six 
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years old and the oldest was 90 years old. This confirms that the swabs have been successful 
in obtaining samples. This result is higher than documented in other studies, most studies 
have much lower values of colonisation of <35% (82, 83, 105-109), however one paper does 
state a nasal colonisation rate of 52.3% (110). These differences in values could be due to 
multiple reasons; for example all of the aforementioned papers are analysing nasal swabs, 
whereas the majority of patients in this study have provided a nasopharyngeal swab, although 
in this study there is little difference between the two sample types. Different detection 
methods, populations and cultural differences may also all result in varying colonisation 
rates. 
When comparing the different population groups and types of swabs there was little 
difference. Symptomatic participant swabs showed that 61% of participants were S.aureus 
positive, whereas the control group had 69% positivity. The nasopharyngeal swabs grew 
S.aureus in 64% of cases, whereas the nasal swabs were 68%. The main difference observed 
was between the female and male swabs; the female participants grew S.aureus on 54% of 
the swabs, whereas the men grew S.aureus on 77% of the swabs. This is, however, in keeping 
with the literature (84, 85). 
Interestingly, despite there being 12 completely negative swabs out of the 140 tested, all 12 
came from female participants, although there was no explanation for this in any of the 
literature. These negative swabs did come from females of all ages – the youngest was 
11months old and the oldest was 75 years old – and there were the same number of negative 
swabs in both the symptomatic and control groups. There were more negative swabs in the 
nasopharyngeal group (11 negative) compared to the nasal group (one negative) but this was 
to be expected, as there is less mucus etc. in the nasopharynx and so the environment is less 




Despite the overall success of the study, there were some limitations which mean that the 
project could be improved upon. Firstly, the ethical approval took a few extra months than 
expected to be granted, and it was therefore mid-November before any sample collection was 
allowed to take place. The equipment required for sample collection then did not arrive until 
the following January, resulting in further delays. 
Once sample collection began, there was then the issue of which patients to recruit. Any 
patients with symptoms of ILI, as mentioned previously, and who gave informed consent 
were included. It can be argued, however, that a person’s experience and tolerance of flu-like 
symptoms can be quite subjective. Most patients would not choose to bother their GP with 
symptoms of a cold, and so it could be perceived that the patients recruited with the ILI 
symptoms could all be of a similar personality trait, and therefore do not reflect the entire 
population. It can also be viewed that the patients able to see their GP during standard 
working hours are mostly retired or unemployed, with only those who are too sick to work 
able to attend a daytime appointment. There is the alternative viewpoint that those recruited 
with ILI would be representative of the ‘fluC population’, as it has been mentioned before 
that the children and the elderly are most at risk (34, 47, 48). 
Some inpatients from the RLI were recruited, but due to time pressures only nine people out 
of the 147 participants recruited were current inpatients on the respiratory ward. Ideally, it 
would have been a more robust study if more unwell patients were recruited, as this would 
have allowed for stronger conclusions to be drawn. As previous studies have mentioned 
pneumonias and serious complications, it would have been good to recruit more patients with 
this type of diagnosis. In addition to this, if more children had been recruited there would 
have been a greater chance of finding the live virus. Despite having permission and approval 
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to collect samples from the paediatric ward at the RLI, unfortunately no patients were 
suitable to participate in the study during the recruitment period. 
One aspect of the fluC virus that would have been interesting to investigate is whether the 
virus is seasonal, or whether it is present in the population all year round. Due to time 
constraints again, samples were mostly collected in January and February, preventing any 
conclusions from being drawn about when the virus is most prevalent. There is a possibility 
that the main ‘fluC season’ could have been missed without our knowledge. 
When choosing which primers to use for the PCR, there was a limit in the number of papers 
who have used this process. It was agreed to use the primers from the most recent paper 
published at the time (28), and also as this was from a nearby country, there was a greater 
chance of these primers matching any potential fluC viruses in England. One drawback to 
this is that other strains of the fluC virus may have been missed. All available M segments for 
the fluC strains were downloaded from GenBank (101) and were aligned using the MEGA 
software (97). The primers by Salez were searched for, and despite a good overall finding, 
not every strain had the specific primer sequences. This then suggests the possibility that 
some samples that were tested during this study could potentially have been positive for fluC, 
but if it was a different viral strain then it may not have appeared positive on PCR. 
Other issues relating to the PCR arose. Thirty seven samples had negative ND values, which 
would suggest that there was no RNA in the samples at all, so the reliability of either the 
quality of the samples or the use of the ND machine needs to be questioned. The nasal swabs 
had to be resuspended in PBS as the swabs did not contain any transport medium. As none of 
these samples came out positive on PCR it could appear as if no RNA was extracted from the 
samples, even though the samples actually all had positive ND values. 
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Another issue with the PCR is that it may not have been optimised. The positive control is 
supposed to have a CT value of 28, but even when comparing three different master mixes 
the CT value still came out above 30. This could suggest that if a sample had a small amount 
of the RNA in it, it could take more than the 45 cycles of the PCR to be amplified and 
detected, possibly causing positive samples to appear negative. 
The samples prepared for deep sequencing were made using a process which creates a very 
small white pellet. In all but one of the samples this pellet was not visible, and so there is a 
chance that either there was no RNA in the samples and therefore no pellet, or that the pellet 
could have accidentally been discarded with the supernatant. The pellet then had to be 
resuspended in 3µl of solution, which is also a very small amount to be frozen and 
transported for deep sequencing, so again there is a chance that it will appear as if there is 
nothing in the sample. Also due to time constraints, the deep sequencing results were unable 
to be analysed, however further work will be done to interpret the results. 
The final limitations to the study were in relation to the analysis of the ELISA results. 
Positive and negative control sera were sent by Nicolas Salez for use in the ELISAs. Despite 
there being a big difference between the readings for the two controls, the negative control 
could be perceived as not being a true negative, as it had a much higher reading than the 
‘blank’ wells. When no antigen was stuck down in the wells containing serum samples, the 
negative reading still gave a higher reading than the background wells without serum 
samples, suggesting that there might be some non-specific binding.  
In order to estimate the IgG concentrations in each sample, the standard concentration curves 
were used. Based upon the straight part of the curve, an estimation of the equation of this part 
of the curve was used in order to calculate the approximate concentration of IgG in each 
sample. This can be argued as a matter of personal preference as to where to choose the 
points for the ‘straight’ aspect, and so in order to avoid this problem the same points were 
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used for each plate. This, however, causes its own problems, as each curve differs, and hence 
the values could be deemed as inaccurate. This also becomes clearer when looking at the total 
IgG concentrations for the samples; most samples fall either above or below the normal range 
due to the rough calculations and estimations used. 
Further issues arose when deciding which samples to class as positive and negative. Using 
Salez’s method gave a seropositivity rate of 82%, whereas using the 1.96 SD method gave a 
seropositivity rate of 77%, which although both give similar values, they could be interpreted 
differently. When reading the literature, most articles will not mention how they calculated 
which samples were positive and negative, despite this process taking place. It seems to be a 
process without a clear and agreed upon method, and so depending upon which method used 
the results will vary. This could potentially mean that the results from this study either over 
or under estimate the number of samples which were positive. 
IV.VI Future 
This study has provided a good foundation for future work; however there are many areas 
which can be built upon. Firstly, in order to get a good impression of the seasonality of fluC, 
samples would need to be collected all year round. Ideally if this could be continued over a 
few years, then it could be determined whether the virus is around in certain seasons, all year 
round, or simply has random epidemics that cannot be predicted. 
Despite a reasonable number of people being recruited for this study, there was an uneven 
range of age groups, as more patients were recruited in the 20-29 and 50-59 age groups. If 
this project was to be taken forward, more patients would need to be recruited from other age 
groups in order to get a more accurate picture of antibody levels etc. in the general 
population. In particular, more focus needs to be placed on obtaining paediatric samples, as it 
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is children who are both most likely to become infected with the virus and to have more 
severe symptoms. 
Further emphasis should also be placed on recruiting those with respiratory conditions. As 
fluC is a respiratory virus, it would seem logical that those with pre-existing lung conditions 
would be more susceptible, or would be more severely affected, by a fluC infection. 
Finally, the use of multiple primers when performing PCR would decrease any concerns of 
missing ‘positive’ samples, due to the primer sequence not being present in that specific 
strain of the virus.  
In the long term, routine monitoring of fluC would be ideal, as the gaps in documentation of 
the virus mean that one can only guess at the behaviour of the virus, rather than actively 
following it and predicting the next development, as is the case with fluA. If it was found that 
fluC is as troublesome as fluA and fluB, then an end goal would obviously be the inclusion of 











FluC is a respiratory virus which can cause symptoms varying from mild colds to 
pneumonias with potentially serious complications, particularly in children. Despite this, few 
published articles show studies conducted on this virus and it is not routinely screened for. 
Older papers suggested that fluC would, at best, would cause mild ‘cold’ symptoms but this 
now appears not to be the case. 
This study aimed to investigate whether fluC is prevalent in Lancaster and whether the 
general population have antibodies against the virus. In order to test these aims, 
nasal/nasopharyngeal swabs and serum samples were collected from 148 participants. PCR 
was then performed on the swab samples and the serum samples were analysed using ELISA. 
It was found that every participant had some level of antibody to the virus, despite not all 
serum samples being classed as positive, therefore showing that the fluC virus is prevalent in 
Lancaster and that everyone has been exposed to the virus. Two samples also appeared 
positive on PCR for the fluC virus but, interestingly, both of these samples were in 
asymptomatic participants. 
Due to limited time, not enough participants were recruited to fully analyse and compare the 
average antibody levels in the population etc. It would be of interest to see whether antibody 
levels remain constant into old age, as they do in Japan, or whether levels decrease, as 
appears to be the case in the rest of the world. In order to further strengthen this study, future 
work would also need to recruit people throughout the year to allow for further understanding 
of the seasonality of the virus. 
Overall, this study has met its aims and has been successful in detecting both live virus itself 
and antibodies to fluC, showing that the virus is prevalent in Lancaster and providing further 
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Table 6 – Influenza C IgG Concentration 
This table shows the mean fluC IgG concentration in mg/dl for each participant who provided 
a serum sample. Samples which were classed as positive were coloured green and those 
which were classed as negative were coloured red. The ‘estimation above’ column is for 
those samples which appeared above the IgG curve, when plotted, and so the concentration of 
the IgG samples cannot be accurately measured above the figure given. A dash (-) indicates 
that a serum sample was not provided. 
Sample no. IgG concentration (mg/dl) Estimation above: Positive/Negative 
K001 0.94  Negative 
K002 4.01  Positive 
K003 0.98  Negative 
K004 3.07  Positive 
K005 1.36  Negative 
K006 2.42  Positive 
K007 2.75  Positive 
K008 5.06  Positive 
K009 3.58  Positive 
K010 1.94  Positive 
K011 3.04  Positive 
K012 -   
K013 3.38  Positive 
K014 -   
K015 3.54  Positive 
K016 -   
K017 7.47 5.88 Positive 
K018 1.86  Positive 
K019 3.13  Positive 
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K020 5.37  Positive 
K021 4.72  Positive 
K022 -   
K023 -   
K024 -   
K025 -   
K026 0.56  Negative 
K027 4.37  Positive 
K028 2.94  Positive 
K029 3.56  Positive 
K030 5.97 5.88 Positive 
K031 7.51 5.88 Positive 
K032 5.77 3.12 Positive 
K033 -   
K034 1.35  Positive 
K035 5.96 3.12 Positive 
K036 4.39 3.12 Positive 
K037 3.81 3.12 Positive 
K038 1.80  Positive 
K039 3.50 3.12 Positive 
K040 1.39  Positive 
K041 4.27 3.12 Positive 
K042 2.83  Positive 
K043 5.28 3.12 Positive 
K044 4.57 3.12 Positive 
K045 4.98 3.12 Positive 
K046 -   
K047 4.09 3.12 Positive 
K048 3.25 3.12 Positive 
K049 4.31 3.12 Positive 
K050 1.93  Positive 
136 
 
K051 5.18 3.12 Positive 
K052 3.59 3.12 Positive 
K053 1.71  Positive 
K054 3.60 3.12 Positive 
K055 2.15  Positive 
K056 1.50  Positive 
K057 0.74  Negative 
K058 3.27 3.12 Positive 
K059 1.59  Positive 
K060 1.51  Positive 
K061 2.91  Positive 
K062 3.24 3.12 Positive 
K063 2.49  Positive 
K064 2.83  Positive 
K065 2.67  Positive 
K066 1.60  Positive 
K067 2.49  Positive 
K068 0.74  Negative 
K069 1.61  Positive 
K070 0.28  Negative 
K071 0.77  Negative 
K072 0.39  Negative 
K073 1.57  Positive 
K074 -   
K075 0.67  Negative 
K076 0.89  Negative 
K077 3.04  Positive 
K078 2.76  Positive 
K079 2.49  Positive 
K080 2.90  Positive 
K081 2.99  Positive 
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K082 2.62  Positive 
K083 2.59  Positive 
K084 -   
K085 3.24 3.12 Positive 
K086 1.16  Positive 
K087 1.68  Positive 
K088 0.83  Positive 
K089 2.54  Positive 
K090 2.20  Positive 
K091 0.84  Positive 
K092 3.58 3.12 Positive 
K093 0.77  Negative 
K094 2.96  Positive 
K095 0.24  Negative 
K096 1.42  Positive 
K097 1.41  Positive 
K098 2.21  Positive 
K099 2.58  Positive 
K100 2.33  Positive 
K101 0.62  Negative 
K102 -   
K103 -   
K104 -   
K105 -   
K106 2.13  Positive 
K107 -   
K108 2.05  Positive 
K109 1.12  Positive 
K110 3.39 3.12 Positive 
K111 3.69 3.12 Positive 
K112 3.27 3.12 Positive 
138 
 
K113 2.29  Positive 
K114 2.98  Positive 
K115 4.10 3.13 Positive 
K116 1.14  Negative 
K117 1.08  Negative 
K118 0.57  Negative 
K119 2.03  Positive 
K120 3.19 3.13 Positive 
K121 0.28  Negative 
K122 2.35  Positive 
K123 1.41  Positive 
K124 2.16  Positive 
K125 2.57  Positive 
K126 2.73  Positive 
K127 1.77  Positive 
K128 0.46  Negative 
K129 2.53  Positive 
K130 1.51  Positive 
K131 1.69  Positive 
K132 2.79  Positive 
K133 0.78  Negative 
K134 -   
K135 0.94  Negative 
K136 4.19 3.13 Positive 
K137 5.17 3.13 Positive 
K138 2.86  Positive 
K139 2.70  Positive 
K140 4.48 3.12 Positive 
K141 -   
K142 4.54 3.12 Positive 
K143 5.35 3.12 Positive 
139 
 
K144 1.77  Negative 
K145 5.89 3.12 Positive 
K146 -   
K147 1.90  Negative 


















Table 10 – Total IgG antibody results 
This table shows the mean total IgG concentration in mg/dl for each participant who provided 
a serum sample. Samples which were classed as below the normal range were coloured green 
and those which were classed as above were coloured red. A dash (-) indicates that a serum 
sample was not provided. 


















































































































































































Table 11 – Comparison of FluC and Total IgG Antibodies 
This table compares the mean fluC IgG concentration with the mean total IgG concentration, 
as a percentage. A dash (-) indicates that a serum sample was not provided. 
Sample no. 





K001 0.94  2909.66 0.03
K002 4.01  695.24 0.58
K003 0.98  4924.72 0.02
K004 3.07  595.18 0.52
K005 1.36  637.64 0.21
K006 2.42  293.39 0.82
K007 2.75  483.41 0.57
K008 5.06  658.41 0.77
K009 3.58  612.60 0.58
K010 1.94  732.69 0.26
K011 3.04  1007.91 0.30
K012 -  - - 
K013 3.38  577.23 0.58
K014 -  - - 
K015 3.54  854.46 0.41
K016 -  - - 
K017 7.47 5.8773437 431.68 1.36
K018 1.86  424.14 0.44
K019 3.13  633.59 0.49
K020 5.37  318.91 1.68
K021 4.72  413.00 1.14
K022 -  - - 
K023 -  - - 
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K024 -  - - 
K025 -  - - 
K026 0.56  462.91 0.12
K027 4.37  409.12 1.07
K028 2.94  379.68 0.78
K029 3.56  782.83 0.46
K030 5.97 5.8773437 2834.05 0.21
K031 7.51 5.8773437 2997.30 0.20
K032 5.77 3.1229508 2302.18 0.14
K033 -  - - 
K034 1.35  1931.07 0.07
K035 5.96 3.1229508 2341.04 0.13
K036 4.39 3.1229508 1516.13 0.21
K037 3.81 3.1229508 3289.27 0.09
K038 1.80  1727.36 0.10
K039 3.50 3.1229508 3246.99 0.10
K040 1.39  767.83 0.18
K041 4.27 3.1229508 2502.14 0.12
K042 2.83  3486.47 0.08
K043 5.28 3.1229508 4364.84 0.07
K044 4.57 3.1229508 3811.76 0.08
K045 4.98 3.1229508 2820.84 0.11
K046 -  - - 
K047 4.09 3.1229508 2258.79 0.14
K048 3.25 3.1229508 2040.67 0.15
K049 4.31 3.1229508 2161.52 0.14
K050 1.93  3147.10 0.06
K051 5.18 3.1229508 3382.18 0.09
K052 3.59 3.1230115 2054.70 0.15
K053 1.71  3173.90 0.05
K054 3.60 3.1230115 4751.15 0.07
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K055 2.15  3881.72 0.06
K056 1.50  3617.08 0.04
K057 0.74  2838.12 0.03
K058 3.27 3.1230115 3753.35 0.08
K059 1.59  2242.22 0.07
K060 1.51  5182.95 0.03
K061 2.91  3205.10 0.09
K062 3.24 3.1230115 3433.38 0.09
K063 2.49  905.45 0.28
K064 2.83  670.33 0.42
K065 2.67  1308.37 0.20
K066 1.60  449.46 0.36
K067 2.49  2661.03 0.09
K068 0.74  676.09 0.11
K069 1.61  1024.45 0.16
K070 0.28  939.67 0.03
K071 0.77  1150.95 0.07
K072 0.39  572.16 0.07
K073 1.57  2998.30 0.05
K074 -  - - 
K075 0.67  3673.23 0.02
K076 0.89  2716.19 0.03
K077 3.04  3805.44 0.08
K078 2.76  2862.63 0.10
K079 2.49  5400.34 0.05
K080 2.90  5504.65 0.05
K081 2.99  4198.77 0.07
K082 2.62  3213.94 0.08
K083 2.59  4481.09 0.06
K084 -  - - 
K085 3.24 3.1229741 3664.54 0.09
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K086 1.16  2723.17 0.04
K087 1.68  2701.20 0.06
K088 0.83  3264.07 0.03
K089 2.54  3580.50 0.07
K090 2.20  2678.07 0.08
K091 0.84  3877.32 0.02
K092 3.58 3.1229741 3134.89 0.10
K093 0.77  4607.99 0.02
K094 2.96  3034.23 0.10
K095 0.24  1194.62 0.02
K096 1.42  1644.44 0.09
K097 1.41  1589.74 0.09
K098 2.21  1284.18 0.17
K099 2.58  2838.31 0.09
K100 2.33  2180.33 0.11
K101 0.62  3264.56 0.02
K102 -  - - 
K103 -  - - 
K104 -  - - 
K105 -  - - 
K106 2.13  1157.08 0.18
K107 -  - - 
K108 2.05  1337.17 0.15
K109 1.12  1041.22 0.11
K110 3.39 3.1230115 1157.36 0.27
K111 3.69 3.1230115 1780.58 0.18
K112 3.27 3.1230115 756.74 0.41
K113 2.29  1141.43 0.20
K114 2.98  1527.09 0.19
K115 4.10 3.127305 1966.00 0.16
K116 1.14  865.59 0.13
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K117 1.08  1165.90 0.09
K118 0.57  550.04 0.10
K119 2.03  657.90 0.31
K120 3.19 3.127305 2722.52 0.11
K121 0.28  3793.68 0.01
K122 2.35  2663.21 0.09
K123 1.41  876.70 0.16
K124 2.16  1524.80 0.14
K125 2.57  1447.43 0.18
K126 2.73  1144.51 0.24
K127 1.77  2464.01 0.07
K128 0.46  978.06 0.05
K129 2.53  854.20 0.30
K130 1.51  631.72 0.24
K131 1.69  642.75 0.26
K132 2.79  1024.84 0.27
K133 0.78  624.76 0.12
K134 -  - - 
K135 0.94  745.72 0.13
K136 4.19 3.127305 1240.99 0.25
K137 5.17 3.127305 591.61 0.53
K138 2.86  629.62 0.45
K139 2.70  486.98 0.56
K140 4.48 3.1249885 1720.23 0.18
K141 -  - - 
K142 4.54 3.1249885 1695.54 0.18
K143 5.35 3.1249885 1207.33 0.26
K144 1.77  747.83 0.24
K145 5.89 3.1249885 1645.34 0.19
K146 -  - - 
K147 1.90  2122.29 0.09
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Table 15 – Staphylococcus plate results 
This table shows the results of the Staphylococcus-selective plates, used to detect the 
presence of Staphylococci on the nasal and nasopharyngeal swabs. A result of ‘Y’ indicates 
positive growth and ‘N’ indicates no growth. N/A indicates that a plate result was not 
available for that participant.  
Sample Date streaked Date checked Staphylococcus 
present? 
Coagulase +ve? 
K001 N/A N/A N/A N/A 
K002 N/A N/A N/A N/A 
K003 N/A N/A N/A N/A 
K004 16/12/2014 18/12/2014 Y N 
K005 16/12/2014 18/12/2014 Y Y 
K006 17/12/2014 19/12/2014 Y Y 
K007 17/12/2014 19/12/2014 Y Y 
K008 17/12/2014 19/12/2014 Y Y 
K009 17/12/2014 19/12/2014 Y Y 
K010 17/12/2014 19/12/2014 Y N 
K011 17/12/2014 19/12/2014 Y Y 
K012 17/12/2014 19/12/2014 N N 
K013 17/12/2014 19/12/2014 Y Y 
K014 18/12/2014 19-22/12/14 Y Y 
K015 18/12/2014 19-22/12/14 Y N 
K016 18/12/2014 19-22/12/14 Y N 
K017 06/01/2015 08/01/2015 Y N 
K018 06/01/2015 08/01/2015 Y Y 
K019 06/01/2015 08/01/2015 Y N 
K020 06/01/2015 08/01/2015 Y Y 
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K021 06/01/2015 08/01/2015 Y Y 
K022 06/01/2015 08/01/2015 Y Y 
K023 06/01/2015 08/01/2015 Y N 
K024 06/01/2015 08/01/2015 Y Y 
K025 06/01/2015 08/01/2015 Y Y 
K026 N/A N/A N/A N/A 
K027 N/A N/A N/A N/A 
K028 06/01/2015 08/01/2015 Y Y 
K029 08/01/2015 12/01/2015 Y N 
K030 08/01/2015 12/01/2015 Y Y 
K031 08/01/2015 12/01/2015 Y Y 
K032 08/01/2015 12/01/2015 Y Y 
K033 08/01/2015 12/01/2015 N N 
K034 09/01/2015 12/01/2015 Y Y 
K035 13/01/2015 15/01/2015 Y N 
K036 13/01/2015 15/01/2015 N N 
K037 13/01/2015 15/01/2015 Y Y 
K038 N/A N/A N/A N/A 
K039 N/A N/A N/A N/A 
K040 N/A N/A N/A N/A 
K041 13/01/2015 15/01/2015 Y Y 
K042 13/01/2015 14/01/2015 Y Y 
K043 13/01/2015 15/01/2015 Y Y 
K044 13/01/2015 15/01/2015 Y N 
K045 14/01/2015 16/01/2015 Y N 
K046 14/01/2015 15/01/2015 Y Y 
K047 14/01/2015 15/01/2015 Y Y 
K048 14/01/2015 15/01/2015 Y Y 
K049 14/01/2015 15/01/2015 Y Y 
K050 14/01/2015 15/01/2015 Y Y 
K051 15/01/2015 19/01/2015 Y Y 
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K052 15/01/2015 19/01/2015 N N 
K053 16/01/2015 19/01/2015 Y Y 
K054 16/01/2015 19/01/2015 Y Y 
K055 16/01/2015 19/01/2015 Y Y 
K056 16/01/2015 19/01/2015 Y Y 
K057 16/01/2015 19/01/2015 Y Y 
K058 16/01/2015 19/01/2015 Y N 
K059 16/01/2015 19/01/2015 Y Y 
K060 16/01/2015 19/01/2015 Y Y 
K061 16/01/2015 19/01/2015 Y N 
K062 16/01/2015 19/01/2015 Y Y 
K063 16/01/2015 19/01/2015 Y Y 
K064 16/01/2015 19/01/2015 Y N 
K065 19/01/2015 21/01/2015 Y N 
K066 19/01/2015 21/01/2015 Y N 
K067 20/01/2015 21/01/2015 Y Y 
K068 20/01/2015 23/01/2015 Y Y 
K069 20/01/2015 23/01/2015 Y Y 
K070 20/01/2015 23/01/2015 Y Y 
K071 20/01/2015 23/01/2015 Y Y 
K072 20/01/2015 21/01/2015 Y Y 
K073 20/01/2015 21/01/2015 Y Y 
K074 20/01/2015 23/01/2015 N N 
K075 21/01/2015 23/01/2015 N N 
K076 21/01/2015 23/01/2015 Y N 
K077 21/01/2015 23/01/2015 Y Y 
K078 22/01/2015 26/01/2015 Y Y 
K079 22/01/2015 26/01/2015 Y Y 
K080 22/01/2015 26/01/2015 Y Y 
K081 22/01/2015 26/01/2015 Y Y 
K082 22/01/2015 26/01/2015 Y N 
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K083 22/01/2015 26/01/2015 Y Y 
K084 23/01/2015 26/01/2015 Y Y 
K085 23/01/2015 26/01/2015 Y Y 
K086 23/01/2015 26/01/2015 Y N 
K087 23/01/2015 26/01/2015 Y Y 
K088 26/01/2015 28/01/2015 N N 
K089 26/01/2015 28/01/2015 Y Y 
K090 26/01/2015 28/01/2015 Y Y 
K091 26/01/2015 28/01/2015 Y Y 
K092 26/01/2015 28/01/2015 Y Y 
K093 26/01/2015 28/01/2015 Y Y 
K094 26/01/2015 28/01/2015 Y Y 
K095 26/01/2015 28/01/2015 Y Y 
K096 28/01/2015 30/01/2015 Y N 
K097 28/01/2015 30/01/2015 Y N 
K098 28/01/2015 30/01/2015 Y N 
K099 28/01/2015 30/01/2015 Y N 
K100 28/01/2015 30/01/2015 Y N 
K101 28/01/2015 30/01/2015 Y Y 
K102 28/01/2015 30/01/2015 Y Y 
K103 29/01/2015 02/02/2015 Y Y 
K104 29/01/2015 02/02/2015 Y N 
K105 29/01/2015 02/02/2015 Y Y 
K106 29/01/2015 02/02/2015 Y Y 
K107 29/01/2015 02/02/2015 Y N 
K108 30/01/2015 02/02/2015 Y N 
K109 30/01/2015 02/02/2015 Y Y 
K110 02/02/2015 05/02/2015 Y N 
K111 02/02/2015 04/02/2014 Y Y 
K112 02/02/2015 04/02/2015 Y Y 
K113 02/02/2015 05/02/2015 Y N 
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K114 02/02/2015 03/02/2015 Y Y 
K115 02/02/2015 03/02/2015 Y Y 
K116 02/02/2015 05/02/2015 Y N 
K117 04/02/2015 06/02/2015 Y Y 
K118 04/02/2015 06/02/2015 N N 
K119 04/02/2015 06/02/2015 N N 
K120 04/02/2015 06/02/2015 N N 
K121 04/02/2015 06/02/2015 Y N 
K122 04/02/2015 06/02/2015 Y N 
K123 04/02/2015 06/02/2015 Y Y 
K124 05/02/2015 06/02/2015 Y Y 
K125 05/02/2015 09/02/2015 Y Y 
K126 05/02/2015 09/02/2015 N N 
K127 05/02/2015 09/02/2015 Y N 
K128 05/02/2015 09/02/2015 Y Y 
K129 05/02/2015 09/02/2015 Y Y 
K130 05/02/2015 06/02/2015 Y Y 
K131 06/02/2015 09/02/2015 Y Y 
K132 06/02/2015 09/02/2015 Y Y 
K133 06/02/2015 09/02/2015 Y Y 
K134 06/02/2015 09/02/2015 Y Y 
K135 09/02/2015 11/02/2015 Y N 
K136 12/02/2015 16/02/2015 Y Y 
K137 12/02/2015 16/02/2015 Y Y 
K138 12/02/2015 16/02/2015 Y Y 
K139 17/02/2015 19/02/2015 Y N 
K140 17/02/2015 19/02/2015 Y Y 
K141 17/02/2015 19/02/2015 Y Y 
K142 17/02/2015 19/02/2015 Y N 
K143 19/02/2015 23/02/2015 Y Y 
K144 19/02/2015 20/02/2015 Y Y 
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K145 23/02/2015 25/02/2015 N N 
K146 23/02/2015 25/02/2015 Y N 
K147 25/02/2015 27/02/2015 Y Y 
K148 05/05/2015 07/05/2015 Y Y 
 
